<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease - Nannini, LJ - 2013 | Cochrane Library</title> <meta content="Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease - Nannini, LJ - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003794.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease - Nannini, LJ - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003794.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003794.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Combined corticosteroid and long‐acting beta&lt;sub&gt;2&lt;/sub&gt;‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Luis Javier Nannini" name="citation_author"/> <meta content="Hospital E Peron" name="citation_author_institution"/> <meta content="ljnannini@hotmail.com" name="citation_author_email"/> <meta content="Phillippa Poole" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Stephen J Milan" name="citation_author"/> <meta content="Lancaster University" name="citation_author_institution"/> <meta content="Rebecca Holmes" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Rebecca Normansell" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD003794.pub4" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/11/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003794.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003794.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003794.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenergic beta‐2 Receptor Agonists [*therapeutic use]; Bronchodilator Agents [*therapeutic use]; Drug Combinations; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003794.pub4&amp;doi=10.1002/14651858.CD003794.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="1pyM3CVc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003794\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003794\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003794.pub4",title:"Combined corticosteroid and long\\u2010acting beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonist in one inhaler versus placebo for chronic obstructive pulmonary disease",firstPublishedDate:"Nov 10, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003794.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003794.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003794.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003794.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003794.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003794.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003794.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003794.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003794.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003794.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1550 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003794.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-sec-0120"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-sec-0112"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/appendices#CD003794-sec-0125"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/table_n/CD003794StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/table_n/CD003794StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Combined corticosteroid and long‐acting beta<sub>2</sub>‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information#CD003794-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Luis Javier Nannini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information#CD003794-cr-0003">Phillippa Poole</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information#CD003794-cr-0004">Stephen J Milan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information#CD003794-cr-0005">Rebecca Holmes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information#CD003794-cr-0006">Rebecca Normansell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information/en#CD003794-sec-0148">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 November 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003794.pub4">https://doi.org/10.1002/14651858.CD003794.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003794-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003794-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003794-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003794-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003794-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003794-abs-0001" lang="en"> <section id="CD003794-sec-0001"> <h3 class="title" id="CD003794-sec-0001">Background</h3> <p>Both long‐acting beta<sub>2</sub>‐agonists (LABA) and inhaled corticosteroids (ICS) have been recommended in guidelines for the treatment of chronic obstructive pulmonary disease (COPD). Their coadministration in a combination inhaler may facilitate adherence to medication regimens and improve efficacy. </p> </section> <section id="CD003794-sec-0002"> <h3 class="title" id="CD003794-sec-0002">Objectives</h3> <p>To determine the efficacy and safety of combined ICS and LABA for stable COPD in comparison with placebo. </p> </section> <section id="CD003794-sec-0003"> <h3 class="title" id="CD003794-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register of trials, reference lists of included studies and manufacturers' trial registries. The date of the most recent search was June 2013. </p> </section> <section id="CD003794-sec-0004"> <h3 class="title" id="CD003794-sec-0004">Selection criteria</h3> <p>We included randomised and double‐blind studies of at least four weeks' duration. Eligible studies compared combined ICS and LABA preparations with placebo. </p> </section> <section id="CD003794-sec-0005"> <h3 class="title" id="CD003794-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed study risk of bias and extracted data. Dichotomous data were analysed as fixed‐effect odds ratios (OR) or rate ratios (RR) with 95% confidence intervals (95% CI), and continuous data as mean differences with 95% confidence intervals. </p> </section> <section id="CD003794-sec-0006"> <h3 class="title" id="CD003794-sec-0006">Main results</h3> <p>Nineteen studies met the inclusion criteria (with 10,400 participants randomly assigned, lasting between 4 and 156 weeks, mean 42 weeks). Studies used three different combined preparations (fluticasone/salmeterol, budesonide/formoterol or mometasone/formoterol). The studies were generally at low risk of bias for blinding but at unclear or high risk for attrition bias because of participant dropouts. Compared with placebo, both fluticasone/salmeterol and budesonide/formoterol reduced the rate of exacerbations. Mometasone/formoterol reduced the number of participants experiencing one or more exacerbation. Pooled analysis of the combined therapies indicated that exacerbations were less frequent when compared with placebo (Rate Ratio 0.73; 95% CI 0.69 to 0.78, 7 studies, 7495 participants); the quality of this evidence when GRADE criteria were applied was rated as moderate. Participants included in these trials had on average one or two exacerbations per year, which means that treatment with combined therapy would lead to a reduction of one exacerbation every two to four years in these individuals. An overall reduction in mortality was seen, but this outcome was dominated by the results of one study (TORCH) of fluticasone/salmeterol. Generally, deaths in the smaller, shorter studies were too few to contribute to the overall estimate. Further longer studies on budesonide/formoterol and mometasone/formoterol are required to clarify whether this is seen more widely. When a baseline risk of death of 15.2% from the placebo arm of TORCH was used, the three‐year number needed to treat for an additional beneficial outcome (NNTB) with fluticasone/salmeterol to prevent one extra death was 42 (95% CI 24 to 775). All three combined treatments led to statistically significant improvement in health status measurements, although the mean differences observed are relatively small in relation to the minimum clinically important difference. Furthermore, symptoms and lung function assessments favoured combined treatments. An increase in the risk of pneumonia was noted with combined inhalers compared with placebo treatment (OR 1.62, 95% CI 1.36 to 1.94), and the quality of this evidence was rated as moderate, but no dose effect was seen. The three‐year NNTH for one extra case of pneumonia was 17, based on a 12.3% risk of pneumonia in the placebo arm of TORCH. Fewer participants withdrew from the combined treatment arms for adverse events or lack of efficacy. </p> </section> <section id="CD003794-sec-0007"> <h3 class="title" id="CD003794-sec-0007">Authors' conclusions</h3> <p>Combined inhaler therapy led to around a quarter fewer COPD exacerbations than were seen with placebo. A significant reduction in all‐cause mortality was noted, but this outcome was dominated by one trial (TORCH), emphasising the need for further trials of longer duration. Furthermore, we note there has been some debate about the appropriateness of the analysis conducted in the TORCH trial (see Feeback). Increased risk of pneumonia is a concern; however, this did not translate into increased exacerbations, hospitalisations or deaths. Current evidence does not suggest any major differences between inhalers in terms of effects, but nor is the evidence strong enough to demonstrate that all are equivalent. Importantly, we cannot comment on the relative contribution of the individual components of combined therapy to the effects identified, as this review presents only the pair‐wise comparison between combined therapy and placebo. To permit firmer conclusions about the effects of combined therapy, more data are needed, particularly in relation to the profile of adverse events and benefits in relation to different formulations and doses of inhaled ICS. Head‐to‐head comparisons are necessary to determine whether one combined inhaler is better than the others. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003794-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003794-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003794-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003794-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003794-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003794-abs-0003" lang="en"> <h3>Combined inhalers versus placebo for the treatment of chronic obstructive pulmonary disease (COPD) </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence on the effects of combined inhalers in people with COPD when compared with placebo. We particularly focused on whether combined inhalers are a good but safe treatment for adults with COPD. </p> <p><b>Background</b> </p> <p>COPD is a serious respiratory condition that affects millions of people worldwide. In most cases, it is caused by smoking. COPD is often treated by using inhalers. Currently, three types of inhalers combine a steroid and a 'long‐acting beta<sub>2</sub>‐agonist' (LABA). Steroids work by reducing inflammation in the airways, and LABA work by relaxing the muscles in the airways and opening them up. Using combined inhalers is more convenient than taking the two drugs separately but is also more expensive. We looked for evidence on whether giving a combined inhaler is better or worse than giving placebo (dummy inhaler). </p> <p><b>Study characteristics</b> </p> <p>Nineteen studies involving 10,400 people were included in this review. The studies lasted between 4 and 156 weeks. All of the people included in the studies had COPD of different severity. Both men and women were included, and most of the studies included only adults aged 45 or older. </p> <p>All studies compared a combined inhaler with a placebo that was identical in appearance to the combined inhaler, so the people in the trials did not know whether they were taking the drug or the dummy inhaler. Some of the studies included two groups treated with the combined inhaler; one group was getting a higher dose and one group was getting a lower dose. </p> <p>The evidence presented here is current to June 2013.</p> <p>Most of the studies were sponsored by the pharmaceutical industry.</p> <p><b>Key results</b> </p> <p>We found that people receiving a combined inhaler were less likely to have a flare‐up (‘exacerbation’) of their COPD. The chance of having an exacerbation was reduced by about one quarter. </p> <p>A small reduction in the risk of death was seen over three years, although most of the evidence about death comes from one large, long trial called TORCH. According to TORCH, approximately 42 people would need to be treated with a combined inhaler for three years to prevent one death. </p> <p>We also found that people receiving combined inhalers had small improvements in quality of life, symptoms related to COPD and their breathing tests. However, these improvements may not have been very noticeable to them. </p> <p>People treated with combined inhalers were more likely to have a lung infection called pneumonia. Again, most of the evidence about pneumonia comes from the TORCH trial. According to TORCH, when compared with placebo, for approximately every 17 people treated with combined inhaler, one extra person would get pneumonia. </p> <p>People treated with combined inhalers were no more or less likely to experience serious unwanted events, including side effects, during treatment. </p> <p>No consistent differences were found between the three different types of inhalers included in this review. </p> <p>However, it is important to note that we cannot tell from this review whether it is the combination that is important or whether one of the two drugs in the combined inhaler may have had the real impact. </p> <p><b>Quality of the evidence</b> </p> <p>The evidence presented in this review is generally considered to be of moderate quality. Most of the studies did not clearly explain how they decided which people would receive the combined inhaler and which would receive placebo, and this is an important part of a well‐conducted study. Also, more people receiving placebo dropped out of the trials than those receiving a combined inhaler. This often happened because of exacerbations of COPD. This means that by the end of the trial, the groups might have been unbalanced, and this could affect the accuracy of the results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003794-sec-0120" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003794-sec-0120"></div> <h3 class="title" id="CD003794-sec-0121">Implications for practice</h3> <section id="CD003794-sec-0121"> <p>For people with moderate or severe COPD, clinical benefit is derived when a long‐acting beta<sub>2</sub>‐agonist and an inhaled corticosteroid are co‐administered, compared with treatment with placebo, in terms of fewer exacerbations and possibly reduced risk of death. Furthermore, small benefits for quality of life and symptoms are noted. However, the effect of combined treatment on all‐cause mortality is heavily weighted by one trial, which in itself was not reported to show a significant reduction. (This point added value to this review because the <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> study alone did not achieve significance in mortality.) Despite positive effects on exacerbations and mortality, no effect on hospitalisation was reported. Moreover, a paradoxical finding indicates that fluticasone/salmeterol led to an increased risk of pneumonia. The NNTH to cause one additional case of pneumonia may be as low as 17, whereas the NNTB to prevent one death during the study period is 42. </p> <p>Importantly, we have not commented on the relative contribution of the individual components of combined therapy to the effects identified, as this review presents only pair‐wise comparisons between combined therapy and placebo. However, several included studies comprise intervention arms in which the individual components are compared to placebo and to combined therapy, providing information about the contributions of the individual components. We also note the debate about the appropriateness of analysis conducted in the TORCH trial (<a href="#CD003794-sec-0135">Feedback 1</a>, <a href="#CD003794-sec-0139">Feedback 2</a>). Furthermore, whether a combination is better than the two components taken separately was not addressed in this review. </p> <p>Guidelines suggest that patients with symptomatic moderate to severe COPD should be given LABA or LAMA and possibly ICS; therefore it could be argued that this review is redundant. However, this review increased the level of evidence supporting the use of combined therapy (LABA/ICS) in COPD category "D" (<a href="./references#CD003794-bbs2-0088" title="GINA Science Committee. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. http://www.ginasthma.org (accessed 9 July 2013). ">GOLD 2012</a>). On the other hand, this review shows that use of a combination inhaler is not associated with large benefit in terms of symptoms or quality of life over placebo. The high attrition rate presented in many studies (in TORCH, 56% completed in the placebo group) could have overshadowed the benefits of those outcomes. Our review therefore supports the current widely accepted guidance for a stepwise approach to treatment of patients with mild or moderate disease. Combined therapy seems best indicated for COPD patients with post‐bronchodilator FEV<sub>1</sub> &lt; 60% and frequent exacerbations and/or hospitalisations. </p> </section> <h3 class="title" id="CD003794-sec-0122">Implications for research</h3> <section id="CD003794-sec-0122"> <p>Any study should carefully document trial participants using the new GOLD COPD grading criteria. A more standardised approach to recording of serious adverse events such as pneumonia, hospitalisation, intensive care support or death would provide a more accurate picture of the benefits and harms of the long‐term effects of this form of therapy. </p> <p>Pharmacoeconomic analyses would be helpful to assist purchasers of health care in making decisions about the cost‐effectiveness of combined inhalers. Responder analyses should be reported; this might give an idea as to which COPD phenotypes may provide the greatest benefit. </p> <p>Assessment of BDF and MF/F in larger and longer trials is required to reveal whether these preparations confer benefits for mortality similar to those provided by FPS. Head‐to‐head trials of combined inhalers are needed if benefits are to be compared in a robust fashion. Network meta‐analysis may help further elucidate the relative contribution of the individual components of combined therapy to the effects identified, in addition to the information already provided by the multi‐arm trials such as <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>. </p> <p>Combined therapy should be compared with separate administration of long‐acting beta<sub>2</sub>‐agonist and inhaled corticosteroid at different doses in large‐scale multi‐centre studies using a double‐dummy design, to assess whether combined therapy confers benefits over the simple addition of beta<sub>2</sub>‐agonist to different doses of inhaled steroid treatment in separate inhalers. A lower dose of ICS might still confer therapeutic benefit while reducing the incidence of pneumonia. The high attrition rate reported in many studies might be contemplated in future studies, to maintain the capacity of calculated sample size to show significant differences in outcomes such as quality of life, hospitalisation and death rates. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003794-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003794-sec-0022"></div> <div class="table" id="CD003794-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Combined inhalers versus placebo (primary outcomes) for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combined inhalers versus placebo (primary outcomes) for chronic obstructive pulmonary disease (COPD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with COPD<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> combined inhalers </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Combined inhalers versus placebo (primary outcomes)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual exacerbation rates</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1.35</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0.99</b> </p> <p>(0.93 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate ratio 0.73</b> </p> <p>(0.69 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7473</p> <p>(seven studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants with at least one exacerbation</b> </p> <p><b>Duration of six months<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>301 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>251 per 1000</b> </p> <p>(221 to 286)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.78</b> <br/> (0.66 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3141</p> <p>(eight studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p><b>Duration of 18 months<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b><br/> (41 to 59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.82</b> <br/> (0.68 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10129<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia</b> </p> <p><b>Duration of 18 months<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b><br/> (73 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.62</b> <br/> (1.36 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9620<br/> (14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisations due to COPD exacerbations</b> </p> <p><b>Duration of 18 months<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>115 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b><br/> (95 to 121) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.93</b> <br/> (0.81 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9492<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3, 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded because of risk of attrition bias. </p> <p><sup>2</sup>Concerns have been raised about the analysis of the largest study, TORCH. We note that the protocol was published after the trial had recruited (See <a href="#CD003794-sec-0135">Feedback 1</a>, <a href="#CD003794-sec-0139">Feedback 2</a>). No downgrade. </p> <p><sup>3</sup>Weighted mean duration. </p> <p><sup>4</sup>Downgraded because of imprecision. </p> <p><sup>5</sup>Downgraded because of risk of attrition bias and imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003794-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fluticasone/salmeterol (FPS) versus placebo for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fluticasone/salmeterol (FPS) versus placebo for COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with COPD<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> fluticasone/salmeterol (FPS) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fluticasone/salmeterol (FPS) versus placebo (PLA)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>any</b> </p> <p><b>Duration of two years<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>780 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>794 per 1000</b><br/> (771 to 816) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.09</b> <br/> (0.95 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5574<br/> (nine studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>'serious'</b> </p> <p><b>Duration of two years<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>271 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>287 per 1000</b><br/> (261 to 314) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.08</b> <br/> (0.95 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5531<br/> (nine studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Weighted mean duration. </p> <p><sup>2</sup>Downgraded because of risk of attrition bias and imprecision. </p> <p><sup>3</sup>Concerns have been raised about the analysis of the largest study, TORCH. We note that the protocol was published after the trial had recruited (See <a href="#CD003794-sec-0135">Feedback 1</a>, <a href="#CD003794-sec-0139">Feedback 2</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003794-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Budesonide/formoterol (BDF) versus placebo for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Budesonide/formoterol (BDF) versus placebo for COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with COPD<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> budesonide/formoterol (BDF) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Budesonide/formoterol (BDF) versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> —<b>any</b> —<b>320/9<sup>4</sup> </b> </p> <p><b>Duration of nine months <sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>538 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b><br/> (574 to 669) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.42</b> <br/> (1.16 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1552<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> —<b>any</b> —<b>160/9<sup>4</sup> </b> </p> <p><b>Duration of nine months <sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>538 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1000</b><br/> (557 to 652) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.32</b> <br/> (1.08 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>'serious'</b> —<b>320/9<sup>4</sup> </b> </p> <p><b>Duration of 10 months<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>162 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b><br/> (155 to 219) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.17</b> <br/> (0.95 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2476<br/> (four studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>'serious'</b> —<b>160/9<sup>4</sup> </b> </p> <p><b>Duration of nine months <sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b><br/> (102 to 171) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.2</b> <br/> (0.89 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded because of risk of attrition bias and imprecision and heterogeneity.<br/> <sup>2</sup>Downgraded because of risk of attrition bias and imprecision. </p> <p><sup>3</sup>Weighted mean duration. </p> <p><sup>4</sup>Delivered dose. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003794-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Mometasone/formoterol (MF/F) versus placebo for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Mometasone/formoterol (MF/F) versus placebo for COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic obstructive pulmonary disease<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> mometasone/formoterol (MF/F) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Mometasone/formoterol (MF/F) versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> —<b>any</b> —<b>400/10<sup>3</sup> </b> </p> <p><b>Duration of six months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>362 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b><br/> (298 to 424) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.98</b> <br/> (0.75 to 1.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>890<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> —<b>any</b> —<b>200/10<sup>3</sup> </b> </p> <p><b>Duration of six months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>362 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>317 per 1000</b><br/> (260 to 382) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.82</b> <br/> (0.62 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>894<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>serious</b> —<b>400/10<sup>3</sup> </b> </p> <p><b>Duration of six months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b><br/> (50 to 125) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.09</b> <br/> (0.66 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>890<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>serious</b> —<b>200/10<sup>3</sup> </b> </p> <p><b>Duration of six months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b><br/> (32 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.71</b> <br/> (0.41 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>894<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded because of risk of attrition bias, imprecision and heterogeneity.<br/> <sup>2</sup>Downgraded because of risk of attrition bias and imprecision. </p> <p><sup>3</sup>Delivered dose. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003794-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003794-sec-0023"></div> <section id="CD003794-sec-0024"> <h3 class="title" id="CD003794-sec-0024">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in most industrialised countries, and it is projected to be the third leading cause of death worldwide by 2020 (<a href="./references#CD003794-bbs2-0088" title="GINA Science Committee. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. http://www.ginasthma.org (accessed 9 July 2013). ">GOLD 2012</a>). The disease is predominantly caused by smoking. An estimated three million people are affected by COPD in the UK (<a href="./references#CD003794-bbs2-0098" title="National Clinical Guidelines Centre. Management of chronic obstructive pulmonary disease in adults in primary and secondary care. http://publications.nice.org.uk/chronic‐obstructive‐pulmonary‐disease‐cg101 (accessed 9 July 2013). ">NCGC2010</a>). COPD is a heterogeneous syndrome that is characterised by reduced post‐bronchodilator lung function (forced expiratory volume in one second/forced vital capacity (FEV<sub>1</sub>/FVC)) &lt; 0.7 in all patients (<a href="./references#CD003794-bbs2-0088" title="GINA Science Committee. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. http://www.ginasthma.org (accessed 9 July 2013). ">GOLD 2012</a>). Acute bronchodilator reversibility has traditionally been regarded as a characteristic of asthma, and only in the past few years has it been generally acknowledged that this clinical feature is also present in COPD (<a href="./references#CD003794-bbs2-0089" title="HananiaNA , CelliBR , DonohueJF , MartinUJ . Bronchodilator reversibility in COPD. CHESTOct 2011;140(4):1055‐63.. ">Hanania 2011</a>), as it was found in the UPLIFT study (<a href="./references#CD003794-bbs2-0103" title="TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. for the UPLIFT Study Investigators. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine Oct 9 2008;359(15):1543‐54. ">UPLIFT 2008</a>), in which 53% of participants had an increase of at least 200 mL in FEV<sub>1</sub> post‐salbutamol. In TORCH, an increase in predicted FEV<sub>1</sub> of 10% was an exclusion criterion (<a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>). Patients with COPD generally show progressive lung function loss, accompanied by worsening respiratory symptoms (e.g. dyspnoea, cough and sputum) and health status (<a href="./references#CD003794-bbs2-0088" title="GINA Science Committee. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. http://www.ginasthma.org (accessed 9 July 2013). ">GOLD 2012</a>). These clinical features are a result of persisting and progressive airway inflammation (i.e. bronchial infiltration of neutrophils, macrophages, lymphocytes and mast cells) and increasing evidence of autoimmunity (<a href="./references#CD003794-bbs2-0083" title="CosioMG , Saetta , M , AgustiA . Immunologic aspects of chronic obstructive pulmonary disease. New England Journal of Medicine2009;360:2445‐54. ">Cosio 2009</a>). Furthermore, it has been suggested that some phenotypes of COPD involve chronic systemic inflammation that has an impact on co‐morbidities, such as cardiovascular disease (<a href="./references#CD003794-bbs2-0087" title="Garcia‐AymerichJ , Serra PonsI , ManninoDM , MaasAK , MillerDP , DavisKJ . Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax2011;66(7):585‐90. ">Garcia‐Aymerich 2011</a>). </p> </section> <section id="CD003794-sec-0025"> <h3 class="title" id="CD003794-sec-0025">Description of the intervention</h3> <p>This review focusses on combined inhalers that contain both an inhaled corticosteroid (ICS) and a long‐acting beta<sub>2</sub>‐agonist (LABA). </p> <p>ICS, LABA and long‐acting antimuscarinic agents (LAMA) have been shown to be effective in a range of outcomes in COPD. ICS have not been shown to reduce the rate of decline in FEV<sub>1</sub>, although short‐term increases in FEV<sub>1</sub> and significant reductions in exacerbations have been reported (<a href="./references#CD003794-bbs2-0107" title="YangIA , ClarkeMS , SimEH , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3] ">Yang 2012</a>). LABA and LAMA reduce exacerbation frequency and symptoms and improve quality of life. On the basis of the evidence, <a href="./references#CD003794-bbs2-0088" title="GINA Science Committee. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. http://www.ginasthma.org (accessed 9 July 2013). ">GOLD 2012</a> recommends that inhaled steroids should be used in patients with an FEV<sub>1</sub> &lt; 50% predicted (GOLD stages 3 and 4 or quadrant C and D in the 2012 update of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria) and a history of exacerbations (<a href="./references#CD003794-bbs2-0088" title="GINA Science Committee. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. http://www.ginasthma.org (accessed 9 July 2013). ">GOLD 2012</a>). National Institute for Health and Care Excellence (NICE) guidelines recommend either a LABA with an ICS in a combined inhaler, or with a LAMA, if FEV<sub>1</sub> is less than 50% predicted. Furthermore, the guidelines recommended combined ICS/LABA In people with stable COPD with an FEV<sub>1</sub> ≥ 50% who remain breathless or have exacerbations despite maintenance therapy with a LABA (<a href="./references#CD003794-bbs2-0098" title="National Clinical Guidelines Centre. Management of chronic obstructive pulmonary disease in adults in primary and secondary care. http://publications.nice.org.uk/chronic‐obstructive‐pulmonary‐disease‐cg101 (accessed 9 July 2013). ">NCGC2010</a>). </p> </section> <section id="CD003794-sec-0026"> <h3 class="title" id="CD003794-sec-0026">How the intervention might work</h3> <p>The evidence base for the addition of long‐acting beta<sub>2</sub>‐agonists to inhaled steroids in asthma is well established (<a href="./references#CD003794-bbs2-0086" title="DucharmeFM , Ni ChroininM , GreenstoneI , LassersonTJ . Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews2010, Issue 5. [DOI: 10.1002/14651858.CD005535.pub2] ">Ducharme 2010</a>; <a href="./references#CD003794-bbs2-0099" title="Ni ChroininM , GreenstoneI , LassersonTJ , DucharmeFM . Addition of long‐acting beta2‐agonists to inhaled steroids as first line therapy for persistent asthma in steroid‐naive adults and children. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD005307.pub2] ">Ni Chroinin 2009</a>). In asthma, the scientific rationale for combining LABA and ICS in a single inhaler relates to synergy of action. At a molecular level, ICS up‐regulate the expression of beta<sub>2</sub>‐agonist receptors in bronchial smooth muscle. At the same time, LABA increase the genomic actions of ICS by promoting passage to the cellular nuclei. Thus, beta<sub>2</sub>‐agonists and ICS may interact in a beneficial way, with ICS preventing the loss of function of beta<sub>2</sub>‐agonists with long‐term use, whereas beta<sub>2</sub>‐agonists may potentiate the local anti‐inflammatory actions of ICS in people with asthma (<a href="./references#CD003794-bbs2-0081" title="BarnesPJ . Scientific rationale for inhaled combination therapy with long‐acting 2‐agonists and corticosteroids. European Respiratory Journal2002;19:182‐91. ">Barnes 2002</a>). </p> <p>Some of these mechanisms may also be important in COPD. Several possible advantages associated with a combination of therapies have already been shown to improve outcomes. In particular, ICS in combination with LABA may have a greater effect than either treatment alone on the number of exacerbations, or on other outcomes such as quality of life (<a href="./references#CD003794-bbs2-0096" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>; <a href="./references#CD003794-bbs2-0097" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006826.pub2] ">Nannini 2013</a>). One clinical rationale is based on patient convenience, with the expectation that a simplified inhaler regimen may lead to greater treatment adherence (<a href="./references#CD003794-bbs2-0081" title="BarnesPJ . Scientific rationale for inhaled combination therapy with long‐acting 2‐agonists and corticosteroids. European Respiratory Journal2002;19:182‐91. ">Barnes 2002</a>). </p> </section> <section id="CD003794-sec-0027"> <h3 class="title" id="CD003794-sec-0027">Why it is important to do this review</h3> <p>This is an update of a previous review, which considered the effect of combined therapy compared with placebo, as well as both monocomponents separately, in people with COPD (<a href="./references#CD003794-bbs2-0109" title="NanniniL , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta‐agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD003794.pub2] ">Nannini 2004</a>). The availability of several new studies has prompted us to split the review between comparisons with placebo and those with monocomponents. This review summarises the evidence from clinical trials comparing combined ICS and LABA with placebo. Reviews of the comparison between combined therapy and ICS (<a href="./references#CD003794-bbs2-0097" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006826.pub2] ">Nannini 2013</a>) or long‐acting beta<sub>2</sub>‐agonists (<a href="./references#CD003794-bbs2-0096" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>) are published separately. </p> <p>Concerns have been raised recently regarding the safety of LABA in asthma (<a href="./references#CD003794-bbs2-0106" title="WaltersEH , GibsonPG , LassersonTJ , WaltersJAE . Long‐acting beta2‐agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001385.pub2] ">Walters 2007</a>). Moreover, questions have surrounded the validity of summary estimates from clinical trials that assessed exacerbation rates without accounting for follow‐up time or adjustment for between‐participant variability (<a href="./references#CD003794-bbs2-0102" title="SuissaS . Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2006;173(8):842‐6. ">Suissa 2006</a>). Two well‐known COPD guidelines (<a href="./references#CD003794-bbs2-0088" title="GINA Science Committee. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. http://www.ginasthma.org (accessed 9 July 2013). ">GOLD 2012</a>; <a href="./references#CD003794-bbs2-0098" title="National Clinical Guidelines Centre. Management of chronic obstructive pulmonary disease in adults in primary and secondary care. http://publications.nice.org.uk/chronic‐obstructive‐pulmonary‐disease‐cg101 (accessed 9 July 2013). ">NCGC2010</a>) had issued a strong recommendation regarding ICS/LABA combined therapy. But others are more guarded: "Recommendation 5: ACP, ACCP, ATS, and ERS suggest that clinicians may administer combination inhaled therapies (long‐acting inhaled anticholinergics, long‐acting inhaled beta<sub>2</sub>‐agonists, or inhaled corticosteroids) for symptomatic patients with stable COPD and FEV<sub>1</sub> &lt; 60% predicted (Grade: weak recommendation, moderate‐quality evidence)" (<a href="./references#CD003794-bbs2-0080" title="ACP , ACCP , ATS , ERS . Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of Internal Medicine2011;155:179‐91. ">ACP 2011</a>). Finally, the largest randomised controlled trial (RCT) of combined therapy (<a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>) demonstrated a significant reduction in mortality versus placebo (P = 0.052). We wished to see whether other combined inhalers had a similar effect. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003794-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003794-sec-0028"></div> <p>To determine the efficacy and safety of combined ICS and LABA for stable COPD in comparison with placebo. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003794-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003794-sec-0029"></div> <section id="CD003794-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003794-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised, double‐blind, parallel‐group clinical trials of at least four weeks' duration.</p> </section> <section id="CD003794-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adult patients (age &gt; 40 years) with known, stable COPD fulfilling American Thoracic Society (ATS), European Respiratory Society (ERS) or Global Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria. Patients were to be clinically stable with no evidence of an exacerbation for one month before study entry. Patients with significant diseases other than COPD (e.g. with a diagnosis of asthma, cystic fibrosis, bronchiectasis or other lung diseases) were excluded. However, patients with partial reversibility on pulmonary function testing were included. </p> </section> <section id="CD003794-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD003794-list-0001"> <li> <p>Fluticasone propionate/salmeterol versus placebo (FPS).</p> </li> <li> <p>Budesonide/formoterol versus placebo (BDF).</p> </li> <li> <p>Mometasone furoate/formoterol versus placebo (MF/F).</p> </li> </ul> </p> <p>Concomitant therapy was permitted, as long as no systematic difference was noted between treatment groups; however, trials in which participants were randomly assigned to tiotropium and combined ICS/LABA therapy versus tiotropium and placebo were excluded from the review, as this comparison is already considered in <a href="./references#CD003794-bbs2-0092" title="KarnerC , CatesCJ . Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD008532.pub2] ">Karner 2011</a>. </p> </section> <section id="CD003794-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD003794-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003794-list-0002"> <li> <p>Exacerbations, measured as rate or number of participants experiencing an exacerbation.</p> </li> <li> <p>All‐cause mortality.</p> </li> <li> <p>Pneumonia.</p> </li> <li> <p>Hospitalisations due to COPD exacerbation (note that we accepted COPD reported as a serious adverse event as a surrogate marker for this outcome; the internationally recognised definition of a serious adverse event includes a life‐threatening event or one that results in hospitalisation or prolonged hospitalisation). </p> </li> </ul> </p> </section> <section id="CD003794-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003794-list-0003"> <li> <p>Change in forced expiratory volume in 1 second (FEV<sub>1</sub>) and change in forced vital capacity (FVC): trough, peak and average and other measures of pulmonary function. </p> </li> <li> <p>Exercise performance: six‐minute walk and other measures.</p> </li> <li> <p>Quality of life scales: St George's Respiratory Questionnaire (SGRQ), Chronic Respiratory Disease Questionnaire (CRDQ). </p> </li> <li> <p>Symptoms.</p> </li> <li> <p>Inhaled rescue medication used during the treatment period and other concomitant medications used, including antibiotics and steroids. </p> </li> <li> <p>Adverse events: palpitations, tremor, hoarseness/dysphonia, oral candidiasis, cataracts, skin bruising, bone fracture, bone density, plasma cortisol level. </p> </li> <li> <p>Rate of withdrawal due to lack of efficacy or COPD deterioration.</p> </li> <li> <p>Withdrawal due to adverse events.</p> </li> </ul> </p> </section> </section> </section> <section id="CD003794-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003794-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We identified trials using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO; we also handsearched respiratory journals and meeting abstracts (see <a href="./appendices#CD003794-sec-0126">Appendix 1</a> for more details). All records in the Specialised Register coded as 'COPD' were searched using the following terms: </p> <p>(((beta* and agonist*) and long*) or ((beta* and adrenergic*) and long*) and (*steroid or steroid* or corticosteroid*)) or (fluticasone and salmeterol) or Seretide or Advair or (formoterol and budesonide) or Symbicort. </p> <p>The most recent search was done in June 2013. We applied no restrictions on language of publication or publication type. </p> </section> <section id="CD003794-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We reviewed reference lists of all primary studies and review articles for additional references, and we contacted authors of identified randomised trials about other published and unpublished studies. In addition, we consulted the online trial registries of GlaxoSmithKline and AstraZeneca, manufacturers of FPS and BDF, respectively (<a href="http://www.ctr.gsk.co.uk" target="_blank">www.ctr.gsk.co.uk</a>; <a href="http://www.astrazenecaclinicaltrials.com" target="_blank">www.astrazenecaclinicaltrials.com</a>). </p> </section> </section> <section id="CD003794-sec-0040"> <h3 class="title" id="CD003794-sec-0040">Data collection and analysis</h3> <section id="CD003794-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LJN and PP) independently identified abstracts of trials that appeared potentially relevant. Using the full text of each study, these review authors independently selected trials for inclusion in the review. Consensus was by simple agreement, with third party adjudication used to resolve differences. </p> </section> <section id="CD003794-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RN and RH) independently extracted data from included trials. RN entered the data into Review Manager, and this work was checked by RH. In some cases, we estimated information regarding outcomes from graphs. This was performed independently. Data extraction included the following items. </p> <p> <ul id="CD003794-list-0004"> <li> <p><b>Design:</b> method of randomisation, presence and type of run‐in period, study design (parallel, cross‐over). </p> </li> <li> <p><b>Population:</b> age, gender, smoking status, study setting (country, practice setting), inclusion and exclusion criteria. </p> </li> <li> <p><b>Intervention:</b> dose, delivery device, duration. </p> </li> <li> <p><b>Control:</b> concurrent treatments (ipratropium, beta<sub>2</sub>‐agonist, inhaled and systemic corticosteroids). </p> </li> <li> <p><b>Outcomes:</b> as above. </p> </li> </ul> </p> </section> <section id="CD003794-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The risk of bias of included studies was assessed using The Cochrane Collaboration's risk of bias tool (<a href="./references#CD003794-bbs2-0090" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). Two review authors (RN and RH) assessed the risk of bias of all included studies with regard to random sequence generation, allocation concealment, blinding, incomplete outcome data and selective outcome reporting. Each item was assessed as having high, low or unclear risk of bias on the basis of relevant information reported in the randomised controlled trial. </p> </section> <section id="CD003794-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous variables, data are expressed as odds ratios (OR) with 95% confidence intervals (CI). Data for continuous variables were reported as mean differences (MD) with 95% CI. </p> </section> <section id="CD003794-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant.</p> </section> <section id="CD003794-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study sponsors and primary investigators to obtain information that we could not verify by reviewing the study reports. </p> <p>We used reported confidence intervals or P values to calculate standard deviations, or standard errors, when necessary. </p> </section> <section id="CD003794-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>For pooled effects, heterogeneity was assessed by using the I<sup>2</sup> measurement. This estimates the degree of variation between studies not attributable to the play of chance. I<sup>2</sup> was interpreted in relation to the following guidance (<a href="./references#CD003794-bbs2-0090" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p> <ul id="CD003794-list-0005"> <li> <p>0% to 40%: may not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: may represent considerable heterogeneity (<a href="./references#CD003794-bbs2-0090" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </li> </ul> </p> <p>We also considered the Chi<sup>2</sup> test (P value &lt; 0.10). We regarded I<sup>2</sup> as our primary measure of heterogeneity. </p> </section> <section id="CD003794-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We evaluated publication bias by using visual inspection of funnel plots when an adequate number of trials were aggregated in the analyses (more than ten). We recognised that an asymmetrical funnel plot can reflect heterogeneity, outcome reporting bias and small study effects and therefore is not necessarily a reflection of publication bias. </p> </section> <section id="CD003794-sec-0049"> <h4 class="title">Data synthesis</h4> <p>For continuous variables, we used a fixed‐effect mean difference (MD) for outcomes measured on the same metric. A standardised mean difference (SMD) with 95% confidence interval (95% CI) was calculated for outcomes when data were combined from studies using different metrics. All similar studies were pooled using fixed‐effect MD/SMD and 95% CI. </p> <p>For dichotomous variables, we calculated a fixed‐effect odds ratio (OR) with 95% CI. All similar studies were pooled using a fixed‐effect OR and 95% CI. </p> <p>When mean treatment differences were reported, data were entered as generic inverse variance (GIV), provided a standard error for the difference could be extracted or imputed. When this method was used, the effect size was reported from the original papers, for example, as a Rate Ratio (RR). This method (GIV) was not available when the protocol was written for the review, so it was not prespecified. </p> <p>We used pooled OR with 95% CI to calculate numbers needed to treat for an additional beneficial outcome (NNTB) or harm (NNTH) using <a href="./references#CD003794-bbs2-0105" title="Cates CJ. Visual Rx Version 3.0. www.nntonline.net (accessed 9 July 2013). ">Visual Rx</a>. Control event rates were taken from the event rates in the individual trials and are reported with the corresponding duration of the trial because NNTs are time dependent (<a href="./references#CD003794-bbs2-0082" title="CatesC J . Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax2012;68(6):499‐500. [DOI: 10.1136/thoraxjnl‐2012‐202959] ">Cates 2012</a>). </p> </section> <section id="CD003794-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We separated the types of steroids and long‐acting beta<sub>2</sub>‐agonists, and for the new studies included in this update, we also separated differing dosages of the same drug. We planned the following a priori subgroups. </p> <p> <ul id="CD003794-list-0006"> <li> <p>Disease severity (related to baseline FEV<sub>1</sub> and placebo group exacerbation rate) according to GOLD staging of IIA or IIB (moderate COPD, characterised by deteriorating lung function (IIA = FEV<sub>1</sub> ≤ 80% predicted; IIB = ≤ 50% predicted) with progression of symptoms) and III (severe COPD, characterised by severe airflow limitation (FEV<sub>1</sub> &lt; 30% predicted) and the presence of respiratory failure or clinical signs of right heart failure (<a href="./references#CD003794-bbs2-0088" title="GINA Science Committee. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. http://www.ginasthma.org (accessed 9 July 2013). ">GOLD 2012</a>). </p> </li> <li> <p>Prior inhaled corticosteroid plus long‐acting beta<sub>2</sub>‐agonist use (dichotomised as yes/no). </p> </li> <li> <p>Concurrent therapy with routine beta<sub>2</sub>‐agonist (short‐ or long‐acting), corticosteroid (systemic or inhaled) or theophylline (dichotomised as yes/no). </p> </li> <li> <p>Reversibility of airflow obstruction with beta<sub>2</sub>‐agonist therapy (dichotomised as partial/none). Definition: &gt; 12% and &gt; 200 mL from baseline FEV<sub>1</sub> or &gt; 12% post‐bronchodilator (metered‐dose inhaler (MDI) salbutamol 200 to 400 mcg). </p> </li> <li> <p>Dose, duration and delivery method of therapy.</p> </li> </ul> </p> </section> <section id="CD003794-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>For pooled effects, heterogeneity was to be tested by using the I<sup>2</sup> measurement of the degree of variation between studies, not attributable to the play of chance. If heterogeneity was found (I<sup>2</sup> statistic &gt; 30%), a random‐effects model was used to determine the impact of heterogeneity on the overall pooled effect. In addition, the robustness of the results was tested using a sensitivity analysis based on the quality of the trials when possible. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003794-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003794-sec-0052"></div> <section id="CD003794-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD003794-sec-0054"> <h4 class="title">Results of the search</h4> <p>For details of the search history, see <a href="#CD003794-tbl-0005">Table 1</a>. </p> <div class="table" id="CD003794-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Version</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Detail</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First published version—Issue 4, 2003 (all years to April 2002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 34<br/> References retrieved: seven<br/> Studies excluded: three (Cazzola 2000; Chapman 2002; Soriano 2002)<br/> Studies identified from supplementary searching: four (Dal Negro 2003; Hanania 2003—both included; Cazzola 2002a; Cazzola 2004—both excluded).<br/> Studies included: four </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Second published version—Issue 3, 2004 (April 2003 to April 2004)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 12<br/> References retrieved: three (two papers full publications of previously included or cited studies (Dal Negro 2003; Hanania 2003). Handsearching identified two further references to the COSMIC 2003 study<br/> Studies identified from supplementary searching: one (TRISTAN 2003)<br/> New studies included: two<br/> Total studies included: six </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Third published version—Issue 3, 2005 (April 2004 to April 2005)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 52<br/> References retrieved: 46 (references to studies already included/excluded/ongoing: 24)<br/> New unique studies identified: 10 (ongoing studies: two)<br/> New studies included: zero<br/> Total studies included: six </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fourth published version (April 2005 to April 2007)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 66<br/> References retrieved: 27 (references to studies already included/excluded/ongoing)<br/> New unique studies identified: five (ongoing studies: zero)<br/> New studies included: five<br/> Total studies included: 11 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fifth published version (April 2007 to June 2013)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 129</p> <p>New unique studies identified: eight (ongoing studies: zero)</p> <p>New studies included: eight</p> <p>Total studies included: 19</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003794-sec-0055"> <h4 class="title">Included studies</h4> <p>Nineteen studies are included in this review. A previous ongoing study, Morgan 2004, has now been linked to the <a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> trial. For a full description of baseline characteristics, methods used and inclusion and exclusion entry criteria for the individual studies, see <a href="./references#CD003794-sec-0154" title="">Characteristics of included studies</a>. </p> <section id="CD003794-sec-0056"> <h5 class="title">Design</h5> <p>All trials had a randomised, double‐blind, parallel‐group design and were of at least four weeks' duration. Methods of randomisation were described in six studies (<a href="./references#CD003794-bbs2-0002" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>; <a href="./references#CD003794-bbs2-0007" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>; <a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD003794-bbs2-0013" title="NCT00120978 . Advair ‐ CRP study. http://clinicaltrials.gov/show/NCT00120978 (accessed 10 June 2013). [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. ABC (Advair, Biomarkers in COPD) Investigators. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(3):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease [see comment]. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>). The method of blinding was not fully described in all studies. Through correspondence from GlaxoSmithKline, trial methodology was confirmed for <a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>, and AstraZeneca confirmed the methodology for <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>. Study characteristics were sufficiently described in two data sets without journal publication to justify their inclusion in the review (<a href="./references#CD003794-bbs2-0012" title="SCO30002 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?item=SCO30002&amp;type=GSK+Study+ID&amp;studyId=SCO30002 (accessed 10 June 2013). ">SFCT01</a> and <a href="./references#CD003794-bbs2-0011" title="Evaluation of novel endpoints in subjects with chronic obstructive pulmonary disease (COPD) in a randomized, double‐blind, placebo‐controlled study of treatment with fluticasone propionate/salmeterol 500/50mcg combination and its individual components, fluticasone propionate 500mcg and salmeterol 50mcg. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?item=SCO104925&amp;type=GSK+Study+ID&amp; studyId=SCO104925 (accessed 8 June 2013). ">SCO104925</a>). </p> </section> <section id="CD003794-sec-0057"> <h5 class="title">Participants</h5> <p>A total of 10,400 participants were randomly assigned to interventions within studies included in this review. Participants suffered from COPD, with variable definitions of COPD and reversibility. COPD was defined by national or international criteria as follows: ATS (<a href="./references#CD003794-bbs2-0006" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference November 14‐15, Arlington, Virginia. 2003:Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. . http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3007&amp;studyId=0A633AAD‐F2BD‐4DA0‐B6A4‐19A812646565&amp;compound=SFCA3007&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>); ERS (<a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>; <a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>); or GOLD (<a href="./references#CD003794-bbs2-0001" title="BarnesNC , QiuY , PavordI , ParkerD , JohnsonM , ThompsonM , et al. Salmeterol/fluticasone propionate (SFC) anti‐inflammatory effects in COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 320]. BarnesNC , QiuY‐S , PavordID , ParkerD , DavisPA , ZhuJ , et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. American Journal of Respiratory &amp; Critical Care Medicine2006;173(7):736‐43. QiuY , ParkerD , BarnesNC , JohnsonM , PavordL , et al. The effect of salmeterol/fluticasone propionate (SFC) on eosinophils and mast cells in COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:A43 [Poster F36]. QiuYS , DavisP , ZhuJ , PeacheyL , BarnesNC , PavordI , et al. Anti‐inflammatory effects of salmeterol/fluticasone propionate (SFC) on airway T‐lymphocyte populations in COPD. European Respiratory Journal2005;26 Suppl 49:203s. QiuYS , DavisP , ZhuJ , PeacheyL , BarnesNC , PavordI , et al. Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in COPD: a placebo‐controlled study of endobronchial biopsies. European Respiratory Journal2005;26 Suppl 49:203s. SCO30005 . A 13‐week, double‐blind, parallel‐group, multicentre study to compare the bronchial anti‐inflammatory activity of the combination of salmeterol/fluticasone propionate (SERETIDE™/ADVAIR™/VIANI™) 50/500 mcg twice daily compared with placebo twice daily in patients with chronic obstructive pulmonary disease. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30005&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30005 (accessed 10 June 2013). ZhuJ , QiuY , BarnesNC , JohnsonM , PavordI , JefferyPK . The effect of salmeterol/fluticasone propionate (SFC) on pro‐inflammatory gene expression in COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:A43 [Poster F6]. ">Barnes 2006</a>; <a href="./references#CD003794-bbs2-0002" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>; <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD003794-bbs2-0004" title="Dal NegroR , MichelettoC , TrevsianF , TognellaS . [A98] Salmeterol and fluticasone 50ug/250ug BiD versus salmeterol 50ug bid and versus placebo in the long term treatment of COPD. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002. Dal NegroRW , PomariC , TognellaS , MichelettoC . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a>; <a href="./references#CD003794-bbs2-0007" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>; <a href="./references#CD003794-bbs2-0013" title="NCT00120978 . Advair ‐ CRP study. http://clinicaltrials.gov/show/NCT00120978 (accessed 10 June 2013). [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. ABC (Advair, Biomarkers in COPD) Investigators. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(3):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease [see comment]. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD003794-bbs2-0019" title="SCO100540 . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500µg BD, compared with placebo via Accuhaler™, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=100540&amp;studyId=A8F0EC6F‐5ECE‐4FA6‐9852‐FBA8CC004B75&amp;compound=100540&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 9 July 2013). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD). Chest2006;130(4):182s. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50µg/fluticasone propionate 500µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology2006;11(Suppl 5):A150. ">Zheng 2006</a>). In seven studies, definitions were not specified or were based on lung function tests and smoking history (<a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a>; <a href="./references#CD003794-bbs2-0009" title="CelliB , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28(Suppl 50):764s. MakeB , EmmettA , CraterG , O'DellD , KalbergC . Improvement in exercise endurance time (EET) with fluticasone propionate/salmeterol correlations with spirometry and plethysmography. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006. O'DonnellDE , SciurbaF , CelliB , MahlerDA , WebbKA , KalbergCJ , et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest2006;130(3):647‐56. SCO40030 . A randomized, double‐blind, placebo‐controlled, parallel group clinical trial evaluating the effect of the fluticasone propionate/salmeterol combination product 250/50mcg bid via DISKUS and salmeterol 50mcg bid via DISKUS on lung hyperinflation in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SCO40030&amp;studyId=8CE29C37‐5F7D‐4461‐B1A6‐1A1FDA5981A6&amp;compound=SCO40030&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). ">O'Donnell 2006</a>; <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a>; <a href="./references#CD003794-bbs2-0011" title="Evaluation of novel endpoints in subjects with chronic obstructive pulmonary disease (COPD) in a randomized, double‐blind, placebo‐controlled study of treatment with fluticasone propionate/salmeterol 500/50mcg combination and its individual components, fluticasone propionate 500mcg and salmeterol 50mcg. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?item=SCO104925&amp;type=GSK+Study+ID&amp; studyId=SCO104925 (accessed 8 June 2013). ">SCO104925</a>; <a href="./references#CD003794-bbs2-0012" title="SCO30002 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?item=SCO30002&amp;type=GSK+Study+ID&amp;studyId=SCO30002 (accessed 10 June 2013). ">SFCT01</a>; <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>). Participant populations in the studies suffered from moderate to very severe COPD, with the exception of <a href="./references#CD003794-bbs2-0002" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>, in which participants with mild COPD were also enrolled, and <a href="./references#CD003794-bbs2-0013" title="NCT00120978 . Advair ‐ CRP study. http://clinicaltrials.gov/show/NCT00120978 (accessed 10 June 2013). [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. ABC (Advair, Biomarkers in COPD) Investigators. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(3):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease [see comment]. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>, in which enrolled participants had FEV<sub>1</sub> &lt; 80% predicted. Two studies enrolled participants with reversible or non‐reversible COPD (<a href="./references#CD003794-bbs2-0006" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference November 14‐15, Arlington, Virginia. 2003:Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. . http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3007&amp;studyId=0A633AAD‐F2BD‐4DA0‐B6A4‐19A812646565&amp;compound=SFCA3007&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>). In <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>, participants were not required to have had previous exacerbations requiring oral steroids or antibiotics to be included in the study. All participants were required to have a smoking history, with the exception of those enrolled in <a href="./references#CD003794-bbs2-0019" title="SCO100540 . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500µg BD, compared with placebo via Accuhaler™, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=100540&amp;studyId=A8F0EC6F‐5ECE‐4FA6‐9852‐FBA8CC004B75&amp;compound=100540&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 9 July 2013). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD). Chest2006;130(4):182s. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50µg/fluticasone propionate 500µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology2006;11(Suppl 5):A150. ">Zheng 2006</a>, which included both smokers and never smokers. </p> </section> <section id="CD003794-sec-0058"> <h5 class="title">Interventions</h5> <p>All 19 studies compared combination therapy with placebo, but the therapies varied. Thirteen studies compared FPS with placebo, four compared BDF and two compared MF/F. In three of the FPS studies, the combination of ICS/LABA was 250 mcg/50 mcg twice daily (<a href="./references#CD003794-bbs2-0004" title="Dal NegroR , MichelettoC , TrevsianF , TognellaS . [A98] Salmeterol and fluticasone 50ug/250ug BiD versus salmeterol 50ug bid and versus placebo in the long term treatment of COPD. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002. Dal NegroRW , PomariC , TognellaS , MichelettoC . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a>; <a href="./references#CD003794-bbs2-0006" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference November 14‐15, Arlington, Virginia. 2003:Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. . http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3007&amp;studyId=0A633AAD‐F2BD‐4DA0‐B6A4‐19A812646565&amp;compound=SFCA3007&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD003794-bbs2-0009" title="CelliB , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28(Suppl 50):764s. MakeB , EmmettA , CraterG , O'DellD , KalbergC . Improvement in exercise endurance time (EET) with fluticasone propionate/salmeterol correlations with spirometry and plethysmography. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006. O'DonnellDE , SciurbaF , CelliB , MahlerDA , WebbKA , KalbergCJ , et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest2006;130(3):647‐56. SCO40030 . A randomized, double‐blind, placebo‐controlled, parallel group clinical trial evaluating the effect of the fluticasone propionate/salmeterol combination product 250/50mcg bid via DISKUS and salmeterol 50mcg bid via DISKUS on lung hyperinflation in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SCO40030&amp;studyId=8CE29C37‐5F7D‐4461‐B1A6‐1A1FDA5981A6&amp;compound=SCO40030&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). ">O'Donnell 2006</a>). In the remainder of the FPS studies, the dose was 500 mcg/50 mcg twice daily. Previous versions of this review did not consider these dosage groups separately, and as the participant numbers are small, this has not been changed in the current update. In <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a> and <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>, the combination ICS/LABA was BDF 320 mcg/9 mcg twice daily, whereas both <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> and <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a> included two combined inhaler active treatment arms: BDF 320 mcg/9 mcg twice daily and 160 mcg/9 mcg twice daily. The two studies of MF/F, <a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a> and <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>, also included two combined inhaler active treatment arms: 400/10 twice daily and 200/10 twice daily. </p> <p>The nature of the run‐in period varied between studies, but studies generally included a two‐ to four‐week washout period from inhaled long‐acting medication. In one study, all participants had a two‐week run‐in treatment with oral corticosteroids, inhaled formoterol and as required a short acting beta<sub>2</sub>‐agonist (SABA) (<a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>). Full details are given in the tables of included studies. </p> <p>Concomitant therapy was as‐needed SABA, short‐acting muscarinic antagonists (SAMA) and, in some studies, tiotropium. In five studies, theophylline was also used. Eleven per cent of participants in <a href="./references#CD003794-bbs2-0006" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference November 14‐15, Arlington, Virginia. 2003:Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. . http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3007&amp;studyId=0A633AAD‐F2BD‐4DA0‐B6A4‐19A812646565&amp;compound=SFCA3007&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a> and all 18 participants in <a href="./references#CD003794-bbs2-0004" title="Dal NegroR , MichelettoC , TrevsianF , TognellaS . [A98] Salmeterol and fluticasone 50ug/250ug BiD versus salmeterol 50ug bid and versus placebo in the long term treatment of COPD. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002. Dal NegroRW , PomariC , TognellaS , MichelettoC . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a> received theophylline, in addition to the study drugs. One participant in the FPS group in <a href="./references#CD003794-bbs2-0002" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a> used theophylline. The exact proportion of participants in <a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> who were taking theophylline was not reported. In <a href="./references#CD003794-bbs2-0019" title="SCO100540 . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500µg BD, compared with placebo via Accuhaler™, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=100540&amp;studyId=A8F0EC6F‐5ECE‐4FA6‐9852‐FBA8CC004B75&amp;compound=100540&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 9 July 2013). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD). Chest2006;130(4):182s. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50µg/fluticasone propionate 500µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology2006;11(Suppl 5):A150. ">Zheng 2006</a>, 2.7% of the active treatment group used theophylline compared with 7.4% of the placebo group. Oral steroids and/or antibiotics were used in all studies in the case of exacerbations. </p> </section> <section id="CD003794-sec-0059"> <h5 class="title">Duration</h5> <p> <ul id="CD003794-list-0007"> <li> <p>13 weeks or less: <a href="./references#CD003794-bbs2-0001" title="BarnesNC , QiuY , PavordI , ParkerD , JohnsonM , ThompsonM , et al. Salmeterol/fluticasone propionate (SFC) anti‐inflammatory effects in COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 320]. BarnesNC , QiuY‐S , PavordID , ParkerD , DavisPA , ZhuJ , et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. American Journal of Respiratory &amp; Critical Care Medicine2006;173(7):736‐43. QiuY , ParkerD , BarnesNC , JohnsonM , PavordL , et al. The effect of salmeterol/fluticasone propionate (SFC) on eosinophils and mast cells in COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:A43 [Poster F36]. QiuYS , DavisP , ZhuJ , PeacheyL , BarnesNC , PavordI , et al. Anti‐inflammatory effects of salmeterol/fluticasone propionate (SFC) on airway T‐lymphocyte populations in COPD. European Respiratory Journal2005;26 Suppl 49:203s. QiuYS , DavisP , ZhuJ , PeacheyL , BarnesNC , PavordI , et al. Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in COPD: a placebo‐controlled study of endobronchial biopsies. European Respiratory Journal2005;26 Suppl 49:203s. SCO30005 . A 13‐week, double‐blind, parallel‐group, multicentre study to compare the bronchial anti‐inflammatory activity of the combination of salmeterol/fluticasone propionate (SERETIDE™/ADVAIR™/VIANI™) 50/500 mcg twice daily compared with placebo twice daily in patients with chronic obstructive pulmonary disease. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30005&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30005 (accessed 10 June 2013). ZhuJ , QiuY , BarnesNC , JohnsonM , PavordI , JefferyPK . The effect of salmeterol/fluticasone propionate (SFC) on pro‐inflammatory gene expression in COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:A43 [Poster F6]. ">Barnes 2006</a>; <a href="./references#CD003794-bbs2-0002" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>; <a href="./references#CD003794-bbs2-0009" title="CelliB , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28(Suppl 50):764s. MakeB , EmmettA , CraterG , O'DellD , KalbergC . Improvement in exercise endurance time (EET) with fluticasone propionate/salmeterol correlations with spirometry and plethysmography. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006. O'DonnellDE , SciurbaF , CelliB , MahlerDA , WebbKA , KalbergCJ , et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest2006;130(3):647‐56. SCO40030 . A randomized, double‐blind, placebo‐controlled, parallel group clinical trial evaluating the effect of the fluticasone propionate/salmeterol combination product 250/50mcg bid via DISKUS and salmeterol 50mcg bid via DISKUS on lung hyperinflation in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SCO40030&amp;studyId=8CE29C37‐5F7D‐4461‐B1A6‐1A1FDA5981A6&amp;compound=SCO40030&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). ">O'Donnell 2006</a>; <a href="./references#CD003794-bbs2-0013" title="NCT00120978 . Advair ‐ CRP study. http://clinicaltrials.gov/show/NCT00120978 (accessed 10 June 2013). [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. ABC (Advair, Biomarkers in COPD) Investigators. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(3):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease [see comment]. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD003794-bbs2-0011" title="Evaluation of novel endpoints in subjects with chronic obstructive pulmonary disease (COPD) in a randomized, double‐blind, placebo‐controlled study of treatment with fluticasone propionate/salmeterol 500/50mcg combination and its individual components, fluticasone propionate 500mcg and salmeterol 50mcg. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?item=SCO104925&amp;type=GSK+Study+ID&amp; studyId=SCO104925 (accessed 8 June 2013). ">SCO104925</a>. </p> </li> <li> <p>24 to 26 weeks: <a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a>; <a href="./references#CD003794-bbs2-0006" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference November 14‐15, Arlington, Virginia. 2003:Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. . http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3007&amp;studyId=0A633AAD‐F2BD‐4DA0‐B6A4‐19A812646565&amp;compound=SFCA3007&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>; <a href="./references#CD003794-bbs2-0019" title="SCO100540 . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500µg BD, compared with placebo via Accuhaler™, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=100540&amp;studyId=A8F0EC6F‐5ECE‐4FA6‐9852‐FBA8CC004B75&amp;compound=100540&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 9 July 2013). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD). Chest2006;130(4):182s. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50µg/fluticasone propionate 500µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology2006;11(Suppl 5):A150. ">Zheng 2006</a>. </p> </li> <li> <p>52 weeks: <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD003794-bbs2-0004" title="Dal NegroR , MichelettoC , TrevsianF , TognellaS . [A98] Salmeterol and fluticasone 50ug/250ug BiD versus salmeterol 50ug bid and versus placebo in the long term treatment of COPD. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002. Dal NegroRW , PomariC , TognellaS , MichelettoC . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a>; <a href="./references#CD003794-bbs2-0012" title="SCO30002 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?item=SCO30002&amp;type=GSK+Study+ID&amp;studyId=SCO30002 (accessed 10 June 2013). ">SFCT01</a>; <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a>; <a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>. </p> </li> <li> <p>130 weeks: <a href="./references#CD003794-bbs2-0007" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>. </p> </li> <li> <p>156 weeks: <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>. </p> </li> </ul> </p> </section> <section id="CD003794-sec-0060"> <h5 class="title">Outcomes</h5> <p>The definition of an exacerbation varied between the included studies, and all definitions are summarised in <a href="./appendices#CD003794-sec-0132">Appendix 2</a>. <a href="./references#CD003794-bbs2-0006" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference November 14‐15, Arlington, Virginia. 2003:Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. . http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3007&amp;studyId=0A633AAD‐F2BD‐4DA0‐B6A4‐19A812646565&amp;compound=SFCA3007&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a> and <a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> withdrew participants whose condition was exacerbated. Lung function, if reported, was measured as FEV<sub>1</sub> or peak expiratory flow (PEF). Quality of life assessment by SGRQ or CRDQ was available for <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a>; <a href="./references#CD003794-bbs2-0006" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference November 14‐15, Arlington, Virginia. 2003:Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. . http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3007&amp;studyId=0A633AAD‐F2BD‐4DA0‐B6A4‐19A812646565&amp;compound=SFCA3007&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a>; <a href="./references#CD003794-bbs2-0012" title="SCO30002 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?item=SCO30002&amp;type=GSK+Study+ID&amp;studyId=SCO30002 (accessed 10 June 2013). ">SFCT01</a>; <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>; <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>; <a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; and <a href="./references#CD003794-bbs2-0019" title="SCO100540 . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500µg BD, compared with placebo via Accuhaler™, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=100540&amp;studyId=A8F0EC6F‐5ECE‐4FA6‐9852‐FBA8CC004B75&amp;compound=100540&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 9 July 2013). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD). Chest2006;130(4):182s. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50µg/fluticasone propionate 500µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology2006;11(Suppl 5):A150. ">Zheng 2006</a>. In addition, breathlessness, cough and sputum score (BCSS) was reported by <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> and <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a>. All‐cause mortality was reported by <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>. </p> </section> </section> <section id="CD003794-sec-0061"> <h4 class="title">Excluded studies</h4> <p>Studies that did not meet the entry criteria of this review are listed in <a href="./references#CD003794-sec-0155" title="">Characteristics of excluded studies</a>, together with a reason for exclusion. </p> </section> </section> <section id="CD003794-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of the risk of bias assessment for each trial is provided in <a href="#CD003794-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD003794-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD003794-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD003794-sec-0063"> <h4 class="title">Allocation</h4> <p>Most of our judgements on allocation procedures were unclear because of the paucity of information provided in the trial reports. We were able to ascertain a low risk of bias in four large studies (<a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>; <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>; <a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>) and in one smaller study (<a href="./references#CD003794-bbs2-0013" title="NCT00120978 . Advair ‐ CRP study. http://clinicaltrials.gov/show/NCT00120978 (accessed 10 June 2013). [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. ABC (Advair, Biomarkers in COPD) Investigators. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(3):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease [see comment]. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>). However, as most included studies are industry‐sponsored, they are extremely likely to have followed gold standards for both random sequence generation and concealment of allocation and therefore to be at low risk of bias. </p> </section> <section id="CD003794-sec-0064"> <h4 class="title">Blinding</h4> <p>All studies were 'double‐blinded', and the authors stated that identical inhaler devices were used to deliver active treatment and placebo; they therefore are likely to be at low risk of performance and detection bias. However, in all trials, further details of participant and assessor blinding were not given. </p> </section> <section id="CD003794-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>Most studies had high attrition rates and therefore were deemed to be at unclear or high risk of bias for all outcomes, including mortality. The <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> trial, however, attempted to follow up all participants for their vital status and therefore was deemed to be at low risk of bias for this outcome. It should be noted that attrition rates reported in the included studies are in keeping with, if not lower than, those expected in COPD trials; therefore these studies are at low risk of bias when compared with similar trials in this field. </p> </section> <section id="CD003794-sec-0066"> <h4 class="title">Selective reporting</h4> <p>Most included studies reported all prespecified outcomes and were deemed to be at low risk of reporting bias. However, as pointed out in feedback received, the trial protocol of the largest included study, <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>, was submitted and published after recruitment of participants (<a href="./references#CD003794-bbs2-0104" title="VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Vestbo 2004</a>). </p> </section> <section id="CD003794-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>Both <a href="./references#CD003794-bbs2-0011" title="Evaluation of novel endpoints in subjects with chronic obstructive pulmonary disease (COPD) in a randomized, double‐blind, placebo‐controlled study of treatment with fluticasone propionate/salmeterol 500/50mcg combination and its individual components, fluticasone propionate 500mcg and salmeterol 50mcg. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?item=SCO104925&amp;type=GSK+Study+ID&amp; studyId=SCO104925 (accessed 8 June 2013). ">SCO104925</a> and <a href="./references#CD003794-bbs2-0012" title="SCO30002 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?item=SCO30002&amp;type=GSK+Study+ID&amp;studyId=SCO30002 (accessed 10 June 2013). ">SFCT01</a> are pharmaceutical company reports that have not been published in the peer‐reviewed literature. However, the trials were sufficiently described to warrant their inclusion and are likely to be at low risk of bias. </p> </section> </section> <section id="CD003794-sec-0068"> <h3 class="title" id="CD003794-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD003794-tbl-0001"><b>Summary of findings for the main comparison</b> Combined inhalers versus placebo (primary outcomes) for chronic obstructive pulmonary disease</a>; <a href="./full#CD003794-tbl-0002"><b>Summary of findings 2</b> Fluticasone/salmeterol (FPS) versus placebo for COPD</a>; <a href="./full#CD003794-tbl-0003"><b>Summary of findings 3</b> Budesonide/formoterol (BDF) versus placebo for COPD</a>; <a href="./full#CD003794-tbl-0004"><b>Summary of findings 4</b> Mometasone/formoterol (MF/F) versus placebo for COPD</a> </p> <section id="CD003794-sec-0069"> <h4 class="title">Primary outcomes</h4> <section id="CD003794-sec-0070"> <h5 class="title">Rate of exacerbations</h5> <section id="CD003794-sec-0071"> <h6 class="title">Pooled results of all combined inhalers versus placebo</h6> <p>When data from seven trials (N = 7495) were pooled, the overall reduction in the rate of exacerbations when FPS or BDF was used was 0.73 (95% CI 0.69 to 0.78; <a href="./references#CD003794-fig-0007" title="">Analysis 1.1</a>); the quality of this evidence when GRADE criteria were used was rated as moderate (<a href="./full#CD003794-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD003794-sec-0072"> <h6 class="title">FPS versus placebo</h6> <p>A significant reduction was noted in the rate of exacerbations with combination therapy when compared with placebo (RR 0.74, 95% CI 0.69 to 0.80, three studies, 4255 participants; <a href="./references#CD003794-fig-0012" title="">Analysis 2.1</a>). This result was not altered by removing <a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>, a study for which the summary estimate may have been biased by inadequate adjustment for between‐participant variability (<a href="./references#CD003794-bbs2-0102" title="SuissaS . Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2006;173(8):842‐6. ">Suissa 2006</a>); see <a href="#CD003794-fig-0002">Figure 2</a>. Additional analyses were performed on exacerbations with specific definitions. Compared with placebo, FPS led to fewer exacerbations requiring oral steroids (RR 0.57, 95% CI 0.52 to 0.63, three studies), less requirement for antibiotics (RR 0.60, 95% CI 0.41 to 0.88) and fewer hospitalisations (RR 0.83, 95% CI 0.7 to 0.97, two studies). </p> <div class="figure" id="CD003794-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.1 Exacerbation rates with combined inhalers versus placebo." data-id="CD003794-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.1 Exacerbation rates with combined inhalers versus placebo. </p> </div> </div> </div> </section> <section id="CD003794-sec-0073"> <h6 class="title">BDF versus placebo</h6> <p>A significant effect on pooled exacerbation rates favoured BDF compared with placebo (RR 0.71, 95% CI 0.62 to 0.81); see <a href="#CD003794-fig-0002">Figure 2</a>. These results are based on data on 3240 participants from four trials (<a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> and <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a>). </p> </section> </section> <section id="CD003794-sec-0074"> <h5 class="title">Number of people experiencing at least one exacerbation</h5> <section id="CD003794-sec-0075"> <h6 class="title">FPS versus placebo</h6> <p>No significant difference was noted between FPS and placebo in terms of the number of participants experiencing at least one exacerbation (OR 0.83, 95% CI 0.64 to 1.07, seven studies, 1817 participants; <a href="./references#CD003794-fig-0013" title="">Analysis 2.2</a>) </p> </section> <section id="CD003794-sec-0076"> <h6 class="title">MF/F versus placebo</h6> <p>The odds ratio for the numbers of participants experiencing at least one exacerbation for the 400/10 strength inhaler was 0.72 (95% CI 0.54 to 0.95, 882 participants; <a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a>; <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>) and 0.76 (95% CI 0.58 to 1.01) for the 200/10 strength inhaler (886 participants; <a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a>; <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>). </p> <p>The point estimates are very similar, and the test for subgroup differences is negative. Thus it cannot be inferred from these results that one strength inhaler is significantly different from another (Chi² = 0.10, df = 1, P = 0.75, I<sup>2</sup> = 0%). </p> <p>Of interest, a post hoc observation was made that the treatment effect is more pronounced when only participants with moderate or severe exacerbations are considered, that is, those requiring antibiotics and/or systemic steroids, emergency treatment or hospitalisation (OR 0.57, 95% CI 0.38 to 0.86 for 400/10; and OR 0.62, 95% CI 0.42 to 0.92 for 200/10; <a href="./references#CD003794-fig-0069" title="">Analysis 4.2</a>). </p> </section> </section> <section id="CD003794-sec-0077"> <h5 class="title">Mortality</h5> <section id="CD003794-sec-0078"> <h6 class="title">Pooled results of all combined inhalers versus placebo</h6> <p>When results were pooled, the overall reduction in mortality with FPS, BDF or MF/F compared with placebo was 0.82 (95% CI 0.68 to 0.99, 16 studies, N = 10,129); the quality of this evidence was rated as moderate (<a href="./full#CD003794-tbl-0001">summary of findings Table for the main comparison</a>). Most of the weight for mortality comes from the <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> trial, which is the only included trial that collected mortality as a primary outcome (<a href="#CD003794-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD003794-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.2 Mortality." data-id="CD003794-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.2 Mortality. </p> </div> </div> </div> <p>Because differing length of follow‐up across studies hinders the calculation of a pooled NNTB, we have tabulated this for each study individually (see <a href="#CD003794-tbl-0006">Table 2</a>). The three‐year NNTB (using the baseline risk of 15.2% in the placebo arm of <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>) to prevent one extra death is 42 (95% CI 24 to 775). </p> <div class="table" id="CD003794-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rates and NNTB of mortality and NNTH of pneumonia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo rate (%)</b> </p> <p><b>mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNTB for mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo rate (%)</b> </p> <p><b>pneumonia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNTH for pneumonia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (24 to 775)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (27 to 12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>292 (164 to 5256)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197 (339 to 131)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249 (149 to 1307)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (82 to 32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (66 to 581)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>674 (379 to 12,149)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (63 to 25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1689 (950 to 30,403)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164 (282 to 109)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>659 (370 to 11,865)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193 (331 to 128)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1187 (668 to 21,377)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>346 (595 to 229)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>340 (191 to 6125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0009" title="CelliB , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28(Suppl 50):764s. MakeB , EmmettA , CraterG , O'DellD , KalbergC . Improvement in exercise endurance time (EET) with fluticasone propionate/salmeterol correlations with spirometry and plethysmography. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006. O'DonnellDE , SciurbaF , CelliB , MahlerDA , WebbKA , KalbergCJ , et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest2006;130(3):647‐56. SCO40030 . A randomized, double‐blind, placebo‐controlled, parallel group clinical trial evaluating the effect of the fluticasone propionate/salmeterol combination product 250/50mcg bid via DISKUS and salmeterol 50mcg bid via DISKUS on lung hyperinflation in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SCO40030&amp;studyId=8CE29C37‐5F7D‐4461‐B1A6‐1A1FDA5981A6&amp;compound=SCO40030&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). ">O'Donnell 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107 (182 to 71)</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003794-sec-0079"> <h6 class="title">FPS versus placebo</h6> <p>The adjusted hazard ratio (HR) from <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> did not identify a significant effect of FPS over placebo (HR 0.825, 95% CI 0.681 to 1.002, P = 0.052; <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>). When the number of deaths in each treatment group was analysed by odds ratio and was combined with data from four other studies, a significant reduction in the odds of death favoured FPS versus placebo (OR 0.79, 95% CI 0.65 to 0.97, N = 5543, 10 studies; <a href="./references#CD003794-fig-0016" title="">Analysis 2.5</a>). Data were separated according to the time point and were subgrouped for data reported at three years, data at one to three years, data at one year and data at six months. </p> </section> <section id="CD003794-sec-0080"> <h6 class="title">BDF versus placebo</h6> <p>The four studies with duration of six months to one year involving 3250 participants did not detect a significant difference in mortality between BDF and placebo (OR 1.05, 95% CI 0.57 to 1.93; <a href="./references#CD003794-fig-0041" title="">Analysis 3.3</a>). </p> </section> <section id="CD003794-sec-0081"> <h6 class="title">MF/F versus placebo</h6> <p>Neither of two very similar studies (<a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a>; <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a>) of 26 weeks' duration and including 1336 participants detected a significant difference between MF/F and placebo (OR 1.35, 95% CI 0.36 to 5.13; <a href="./references#CD003794-fig-0070" title="">Analysis 4.3</a>). </p> <p>However, it should be noted that the confidence intervals for both MF/F and BDF are wide and overlap with those of FPS, so a decrease in mortality with MF/F or BDF cannot be excluded. </p> </section> </section> <section id="CD003794-sec-0082"> <h5 class="title">Pneumonia</h5> <section id="CD003794-sec-0083"> <h6 class="title">Pooled results of all combined inhalers versus placebo</h6> <p>For combined inhalers, the pooled OR for pneumonia is 1.62 (95% CI 1.36 to 1.94, N = 9620, fixed‐effect model) with a moderate level of heterogeneity (I<sup>2</sup> = 32%); the quality of this evidence was rated as moderate (<a href="./full#CD003794-tbl-0001">summary of findings Table for the main comparison</a>). When a random‐effects model of analysis is used, the effect size is reduced but remains significant (OR 1.57, 95% CI 1.01 to 2.42). Most of the weight for this combined result again comes from the TORCH trial, which tested the FPS inhaler. </p> </section> <section id="CD003794-sec-0084"> <h6 class="title">FPS versus placebo</h6> <p>Pooled data from nine FPS trials (N = 5447) show a significant increase in pneumonia among participants treated with FPS in comparison with placebo (OR 1.76, 95% CI 1.46 to 2.14; <a href="#CD003794-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD003794-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.3 Pneumonia." data-id="CD003794-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.3 Pneumonia. </p> </div> </div> </div> </section> <section id="CD003794-sec-0085"> <h6 class="title">BDF versus placebo</h6> <p><a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>, <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> and <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a> reported data on pneumonia; no significant difference was detected between BDF and placebo (OR 0.92, 95% CI 0.57 to 1.47). The test for subgroup differences between BDF and FPS was significant (P = 0.01) when a fixed‐effect model was used. However, when a random‐effects model was applied, no significant difference between subgroups was found (P = 0.65). </p> </section> <section id="CD003794-sec-0086"> <h6 class="title">MF/F versus placebo</h6> <p>Data from <a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a> and <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> suggest no significant difference between treatments in diagnoses of pneumonia (OR 2.39, 95% CI 0.68 to 8.36, N = 1336), but the test for a subgroup difference between MF/F and FPS was negative for both fixed‐effect and random‐effects models (P = 0.64 and 0.66, respectively). </p> <p><a href="#CD003794-tbl-0006">Table 2</a> gives the range of numbers needed to treat for an additional harmful outcome (NNTH) across the studies for pneumonia. A pooled NNTH was not calculated because of the wide differences in duration and the likely impact this would have on the calculation of a pooled event rate. The three‐year NNTH (when the baseline risk of 12.3% was used in the combination therapy arm of <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>) for one extra participant to suffer from pneumonia was 17 (95% CI 27 to 12). </p> </section> </section> <section id="CD003794-sec-0087"> <h5 class="title">Hospitalisations due to COPD</h5> <section id="CD003794-sec-0088"> <h6 class="title">Pooled results of combined inhalers versus placebo</h6> <p>No significant difference was observed between active treatment and placebo for hospitalisation (OR 0.93, 95% CI 0.81 to 1.06, N = 9492; <a href="#CD003794-fig-0005">Figure 5</a>); the quality of this evidence was rated as low (<a href="./full#CD003794-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD003794-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.4 Hospitalisations due to COPD exacerbations." data-id="CD003794-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.4 Hospitalisations due to COPD exacerbations. </p> </div> </div> </div> </section> </section> </section> <section id="CD003794-sec-0089"> <h4 class="title">Secondary outcomes</h4> <section id="CD003794-sec-0090"> <h5 class="title">Quality of life</h5> <section id="CD003794-sec-0091"> <h6 class="title">FPS versus placebo</h6> <p>Treatment with FPS improved SGRQ scores by an average of ‐2.9 units versus placebo (95% CI ‐3.61 to ‐2.18, four studies, N = 3346). Pooled data from <a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> and <a href="./references#CD003794-bbs2-0006" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference November 14‐15, Arlington, Virginia. 2003:Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. . http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3007&amp;studyId=0A633AAD‐F2BD‐4DA0‐B6A4‐19A812646565&amp;compound=SFCA3007&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a> indicated a statistically significant improvement in CRDQ for those treated with FPS compared with placebo (5 units, 95% CI 2.48 to 7.52). </p> </section> <section id="CD003794-sec-0092"> <h6 class="title">BDF versus placebo</h6> <p>A significant effect favoured BDF compared with placebo: ‐3.29 units on the SGRQ (95% CI ‐4.45 to ‐2.13) for the 320/9 strength inhaler, and ‐3.39 units (95% CI ‐4.70 to ‐2.07) for the 160/9 strength inhaler. A high level of heterogeneity was noted when these data were pooled (I<sup>2</sup> = 70%). Random‐effects modelling also generated a significant effect (MD ‐4.11, 95% CI ‐6.18 to ‐2.04 for 320/9; and MD ‐3.39, 95% CI ‐4.70 to ‐2.07 for 160/9). The magnitude of improvement in the <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a> BDF group was 3.9 units from baseline and was not dissimilar from the change scores from post run‐in treatment in <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a> (see graphical presentation of data in the published article, page 916). However, the placebo group deteriorated more in <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>, which possibly reflects the withdrawal of active treatment, with the subsequent loss of predosing effects achieved with high‐dose oral corticosteroids and LABA. In comparison, BDF may have maintained the predosing treatment effects of quality of life more successfully. </p> </section> <section id="CD003794-sec-0093"> <h6 class="title">MF/F versus placebo</h6> <p>Treatment with MF/F resulted in a significant improvement in SGRQ scores when compared with placebo. This was true for both 400/10 (MD ‐3.80, 95% CI ‐5.75 to ‐1.86) and 200/10 (MD ‐3.91, 95% CI ‐6.01 to ‐1.81) inhalers. </p> </section> </section> <section id="CD003794-sec-0094"> <h5 class="title">Symptom score</h5> <section id="CD003794-sec-0095"> <h6 class="title">FPS versus placebo</h6> <p>FPS led to improved symptom scores (transitional dyspnoea index) when compared with placebo (MD 1.04, 95% CI 0.56 to 1.53). </p> </section> <section id="CD003794-sec-0096"> <h6 class="title">BDF versus placebo</h6> <p>Data were pooled for <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a> and <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>. There was a significant effect in favour of BDF when compared with placebo (MD ‐0.63, 95% CI ‐0.90 to ‐0.37). </p> <p><a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> and <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a> reported change from baseline in the breathlessness, cough and sputum score. Both trials described a significant improvement in average score over the treatment period for both strengths of combined inhalers (MD ‐0.43, 95% CI ‐0.59 to ‐0.26 for 320/9; and MD ‐0.44, 95% CI ‐0.60 to ‐0.28 for 160/9). </p> </section> </section> <section id="CD003794-sec-0097"> <h5 class="title">Lung function</h5> <section id="CD003794-sec-0098"> <h6 class="title">FPS versus placebo</h6> <p>Pooled analysis of data was conducted without findings from the <a href="./references#CD003794-bbs2-0004" title="Dal NegroR , MichelettoC , TrevsianF , TognellaS . [A98] Salmeterol and fluticasone 50ug/250ug BiD versus salmeterol 50ug bid and versus placebo in the long term treatment of COPD. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002. Dal NegroRW , PomariC , TognellaS , MichelettoC . Salmeterol &amp; fluticasone 50 microg/250 microg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a> study. Owing to the small size of this study, we were concerned that the standard deviation (SD) represented an inaccurate estimate for the SD of the population, and that the small variance increased the weight of the study out of all proportion to its size. Data pooled from seven studies revealed an MD in predose FEV<sub>1</sub> of 0.16 L (95% CI 0.14 to 0.19, N = 1408). Pooled data from <a href="./references#CD003794-bbs2-0019" title="SCO100540 . A multi‐centre, randomised, double‐blind, parallel group study to investigate the efficacy and safety of the salmeterol/fluticasone propionate combination at a strength of 50/500µg BD, compared with placebo via Accuhaler™, added to usual chronic obstructive pulmonary disease (COPD) therapy, in subjects with COPD for 24 weeks. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=100540&amp;studyId=A8F0EC6F‐5ECE‐4FA6‐9852‐FBA8CC004B75&amp;compound=100540&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 9 July 2013). ZhengJ , ZhongN , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of fluticasone propionate 500 mg/salmeterol 50 mg combined via diskus/accuhaler in Chinese patients with chronic obstructive pulmonary disease (COPD). Chest2006;130(4):182s. ZhongN , ZhengJ , YangL , WuY , ChenP , WenZ , et al. The efficacy and safety of salmeterol 50µg/fluticasone propionate 500µg combined via accuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Respirology2006;11(Suppl 5):A150. ">Zheng 2006</a> and <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> for postdose FEV<sub>1</sub> indicated a significant improvement in favour of FPS over placebo of 0.09 L (95% CI 0.07 to 0.11). Results from <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> demonstrate a clear improvement in average 0‐ to 12‐hour FEV<sub>1</sub> for inhalers of both strengths. </p> </section> <section id="CD003794-sec-0099"> <h6 class="title">BDF versus placebo</h6> <p>FEV<sub>1</sub> data for mean percentage change from baseline were reported by two trials (<a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>). There was a significant increase in FEV<sub>1</sub> in favour of BDF versus placebo (MD 14.40% 95%CI 11.91 to 16.90). </p> <p>Predose FEV<sub>1</sub> and one hour postdose FEV<sub>1</sub> data were reported by one study, which included 858 participants (<a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a>). A significant improvement was noted for both outcomes for combined inhalers of both strengths compared with placebo. <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> reported average 12‐hour FEV<sub>1</sub> and FEV<sub>1</sub> at 12 hours compared with baseline. Again, a significant improvement was noted for both outcomes and for inhalers of both strengths when compared with placebo. </p> <p>Both <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> and <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a> reported change from baseline morning and evening PEF, with significant benefit over placebo noted for inhalers of both strengths. </p> </section> <section id="CD003794-sec-0100"> <h6 class="title">MF/F versus placebo</h6> <p>Both <a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a> and <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> reported mean change from baseline in predose FEV<sub>1</sub> at 13 weeks and demonstrated a significant improvement for both 400/10 (MD 114.64, 95% CI 77.79 to 151.50) and 200/10 (MD 66.00, 95% CI 14.37 to 117.63) inhalers when compared with placebo. It should be noted that no significant difference was seen between the 400/10 and 200/10 groups (test for subgroup differences: Chi<sub>2</sub> = 2.77, df = 1, P = 0.10). </p> <p>Mean change from baseline FEV<sub>1</sub> area under the curve (AUC) 0 to 12 hours is also reported by <a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a> and <a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> and shows significant improvement in favour of active treatment for inhalers of both strengths (MD 162.04, 95% CI 126.54 to 197.53 for 400/10; and MD 122.01, 95% CI 86.64 to 157.39 for 200/10). </p> </section> </section> <section id="CD003794-sec-0101"> <h5 class="title">Rescue medication</h5> <section id="CD003794-sec-0102"> <h6 class="title">FPS versus placebo</h6> <p>Pooled data from <a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> and <a href="./references#CD003794-bbs2-0006" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference November 14‐15, Arlington, Virginia. 2003:Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 250mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. . http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3007&amp;studyId=0A633AAD‐F2BD‐4DA0‐B6A4‐19A812646565&amp;compound=SFCA3007&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a> indicated a significant reduction in mean puffs per day of short‐acting beta<sub>2</sub>‐agonist usage for FPS versus placebo (MD ‐1.19 puffs/d, 95% CI ‐1.83 to ‐0.55). </p> <p><a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> reported significant increases in the percentage of nights with no awakenings requiring short‐acting beta<sub>2</sub>‐agonist in favour of FPS versus placebo (5.7% vs ‐4.3%, respectively; P &lt; 0.031). </p> <p><a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> reported a significant difference in median percentage of days without use of relief medication (FPS 14% vs placebo 0%, P &lt; 0.001). </p> </section> <section id="CD003794-sec-0103"> <h6 class="title">BDF versus placebo</h6> <p>BDF treatment reduced the requirement for reliever medication when compared with placebo. Combined results of <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> and <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a> for the 320/9 strength inhaler show a reduction in use of rescue medication when compared with placebo (‐0.98 puffs/d, 95% CI ‐1.18 to ‐0.79). Pooled results from <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> and <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a> compare the 160/9 strength inhaler with placebo and also reveal a reduction in the use of rescue medication (‐1.28 puffs/d, 95% CI ‐1.55 to ‐1.00) </p> </section> </section> <section id="CD003794-sec-0104"> <h5 class="title">Safety and tolerability</h5> <section id="CD003794-sec-0105"> <h6 class="title">FPS versus placebo</h6> <p>No significant difference was noted between FPS and placebo in the occurrence of overall reported adverse events (OR 1.09, 95% CI 0.95 to 1.25) or serious adverse events (OR 1.08, 95% CI 0.95 to 1.23, N = 5574, nine studies). In both cases, the quality of evidence was rated as low (<a href="./full#CD003794-tbl-0002">summary of findings Table 2</a>). </p> <p>Pneumonia, candidiasis, nasopharyngitis, hoarseness and upper respiratory tract infection (URTI) occurred more frequently among FPS‐treated participants. </p> <p> <ul id="CD003794-list-0008"> <li> <p>Pneumonia: OR 1.80, 95% CI 1.49 to 2.18, nine studies, N = 5447.</p> </li> <li> <p>Candidiasis: OR 5.73, 95% CI 3.07 to 10.67, seven studies, N = 2039.</p> </li> <li> <p>Hoarseness: OR 8.79, 95% CI 1.11 to 69.62, two studies, N = 585.</p> </li> <li> <p>Nasopharyngitis: OR 1.28, 95% CI 1.05 to 1.56, two studies, N = 3535.</p> </li> <li> <p>URTI: OR 1.23, 95% CI 1.04 to 1.47, five studies, N = 4963.</p> </li> </ul> </p> </section> <section id="CD003794-sec-0106"> <h6 class="title">BDF</h6> <p><a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> and <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a> report overall adverse event data and demonstrate a significant difference favouring placebo for inhalers of both 320/9 and 160/9 strength (OR 1.42, 95% CI 1.16 to 1.74 for 320/9; and OR 1.32, 95% CI 1.08 to 1.61 for 160/9). In both cases, the quality of this evidence was rated as low (<a href="./full#CD003794-tbl-0003">summary of findings Table 3</a>). </p> <p>When only serious adverse events were considered, the odds ratios were 1.17 (95% CI 0.95 to 1.45) for the 320/9 strength inhaler and 1.20 (95% CI 0.89 to 1.63) for the 160/9 strength inhaler; again, the quality of this evidence was rated as low (<a href="./full#CD003794-tbl-0003">summary of findings Table 3</a>). </p> <p>No difference was noted between active treatment and placebo for specific adverse events associated with ICS use, with the exception of reported episodes of candidiasis, which were noted to be significantly higher among those receiving active treatment. In addition, more cases of dysphonia were reported in the active treatment group receiving the higher‐dose inhaler, but not in the lower‐dose group. However, the test for subgroup differences was negative, so we cannot be certain of a dose effect. </p> </section> <section id="CD003794-sec-0107"> <h6 class="title">MF/F</h6> <p>No significant difference in the occurrence of overall reported adverse events was reported between either strength of MF/F inhaler and placebo (OR 0.98, 95% CI 0.75 to 1.30 for 400/10; and OR 0.82, 95% CI 0.62 to 1.09 for 200/10). This finding was consistent when only serious adverse events were considered. The quality of this evidence was rated as low in both cases (<a href="./full#CD003794-tbl-0004">summary of findings Table 4</a>). </p> <p>Also, no significant differences were noted between the groups when specific adverse events associated with ICS use were considered, although the overall numbers of events were small. </p> </section> </section> <section id="CD003794-sec-0108"> <h5 class="title">Withdrawals</h5> <section id="CD003794-sec-0109"> <h6 class="title">FPS versus placebo</h6> <p>Significantly fewer withdrawals from treatment were seen with FPS than with placebo (OR 0.69, 95% CI 0.62 to 0.78). Withdrawals due to adverse events and lack of efficacy also occurred less frequently on treatment with FPS than with placebo (withdrawal due to adverse event: OR 0.74, 95% CI 0.64 to 0.86, twelve studies, 5491 participants; withdrawal due to lack of efficacy: OR 0.30, 95% CI 0.22 to 0.41, eight studies, 5115 participants). </p> </section> <section id="CD003794-sec-0110"> <h6 class="title">BDF versus placebo</h6> <p>Data were pooled from <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a>; <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; and <a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a> for withdrawals due to adverse events, and from <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> and <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a> for withdrawals due to lack of efficacy or worsening COPD. </p> <p>A significant difference favoured active treatment in withdrawals due to worsening of COPD symptoms when BDF was compared with placebo (OR 0.56, 95% CI 0.43 to 0.74, three studies, 2392 participants). </p> <p>No significant difference was noted between BDF and placebo in the likelihood of withdrawal due to any adverse event (OR 0.85, 95% CI 0.70 to 1.03). </p> </section> <section id="CD003794-sec-0111"> <h6 class="title">MF/F versus placebo</h6> <p>Significantly fewer withdrawals from treatment were seen with MF/F than with placebo for inhalers of both strengths (OR 0.56, 95% CI 0.40 to 0.77 for 400/10; and OR 0.55, 95% CI 0.40 to 0.76 for 200/10). </p> <p>Of note, a significant difference favoured MF/F when withdrawals due to lack of efficacy of treatment or worsening of COPD symptoms were considered. This was true for inhalers of both strengths (OR 0.24, 95% CI 0.08 to 0.74 for 400/10; and OR 0.31, 95% CI 0.11 to 0.84 for 200/10). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003794-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003794-sec-0112"></div> <section id="CD003794-sec-0113"> <h3 class="title" id="CD003794-sec-0113">Summary of main results</h3> <p>We reviewed data from 19 randomised controlled trials (10,400 participants) assessing the efficacy and safety of combined inhaled corticosteroids and long‐acting beta<sub>2</sub>‐agonists versus placebo for the treatment of COPD. Thirteen studies involved a combined inhaler of fluticasone and salmeterol, four involved budesonide and formoterol and two involved mometasone and formoterol. The findings of this review complement those of two others assessing the effects of combination inhalers with their components, that is, LABA or ICS (<a href="./references#CD003794-bbs2-0096" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>; <a href="./references#CD003794-bbs2-0097" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006826.pub2] ">Nannini 2013</a>). Despite the addition of eight new studies for this update, most of the weight is still coming from the <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> study, which is the largest trial of combined therapy (FPS) in COPD. </p> <section id="CD003794-sec-0114"> <h4 class="title">Primary outcomes</h4> <p>The main findings related to the primary outcomes of exacerbations, mortality, pneumonia and hospitalisations appear in the <a href="./full#CD003794-tbl-0001">summary of findings Table for the main comparison</a>. All eligible studies addressed at least one of the primary outcomes. </p> <p>Combined therapy reduced the rate of moderate exacerbations compared with placebo by about a quarter (<a href="./references#CD003794-fig-0007" title="">Analysis 1.1</a>). But, as was found in the Cochrane reviews comparing combined inhalers with LABA alone or ICS alone (<a href="./references#CD003794-bbs2-0097" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006826.pub2] ">Nannini 2013</a>), this did not translate to a statistically significant reduction in COPD hospitalisation rates. One explanation is that those receiving combined treatment who respond may have fewer and/or milder exacerbations, but equally the smaller number of hospitalisations means that less statistical power was present to show a significant difference. On the other hand, adverse effects were more common with combined treatment than with placebo, particularly the development of pneumonia. The NNTH for this outcome in studies of at least 52 weeks' duration varied from 17 to 197. Concern about pneumonia as an adverse event associated with ICS treatment has persisted ever since <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> was published in 2006. Indeed our analysis shows that the excess of pneumonia is seen only with FPS, not with the other combined inhalers. If the <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> study was not included, the significant OR disappeared, but heterogeneity among trials is still evident (<a href="./references#CD003794-fig-0009" title="">Analysis 1.3</a>), making it difficult to decide whether this effect is a true one. This may suggest ongoing difficulties with the accurate identification of pneumonia, or variations in participant populations, actions of medicines or the nature of lower respiratory tract infections and their treatment over the time course of a study. It is also possible that the heterogeneity in the pneumonia outcome is due to differential withdrawal rates. Withdrawal due to lack of efficacy in the FPS subgroup was greater in the placebo arm (<a href="./references#CD003794-fig-0025" title="">Analysis 2.14</a>), as was seen with BDF (<a href="./references#CD003794-fig-0056" title="">Analysis 3.18</a>) and MF/F studies (<a href="./references#CD003794-fig-0075" title="">Analysis 4.8</a>). It is interesting to note that withdrawals due to adverse events were not different between arms in BDF (<a href="./references#CD003794-fig-0055" title="">Analysis 3.17</a>), whereas for MF/F studies, withdrawals due to adverse events were greater in the placebo arm (<a href="./references#CD003794-fig-0076" title="">Analysis 4.9</a>). These findings suggest something different about the three‐year <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> study compared with the others. Whatever the case, it is reassuring that this apparent excess of pneumonia cases did not translate into greater numbers of hospitalisations or exacerbations, or greater mortality rates. In fact, quite the opposite was noted—exacerbation rates and mortality were reduced with combined treatment. </p> <p>We found that treatment with a combined inhaler led to a significant reduction in mortality compared with placebo when data from all studies were pooled. As with other outcomes, <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> had a major influence on mortality; however, it should be noted that the <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> investigators did not claim a significant reduction in mortality with FPS over placebo (P = 0.052). The difference between the study report and the OR reported in this Cochrane review may be due to variations in statistical methods. <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> used a hazard ratio that was adjusted for repeated measurement. This analysis has been the subject of some debate as the study adopted a factorial design but did not report a factorial analysis (see <a href="#CD003794-sec-0135">Feedback 1</a>, <a href="#CD003794-sec-0139">Feedback 2</a>). Furthermore, although mortality was recorded in many of the studies, it was a primary outcome in <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>. In that study, cause‐specific mortality was also reported, but the definition of a primary cause of death continues to pose challenges in a population of patients who may suffer from co‐morbidities such as lung cancer (<a href="./references#CD003794-bbs2-0095" title="McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD ‐ Operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. ">McGarvey 2007</a>). </p> </section> <section id="CD003794-sec-0115"> <h4 class="title">Secondary outcomes</h4> <p>We were unable to pool secondary outcomes and reported results for each type of combined inhaler separately. Although the only way to test whether one product is better than another is a head‐to‐head comparison, we found that the results for all secondary outcomes, except adverse events, were relatively similar, that is, each combined inhaler showed a small benefit over placebo in effects on health‐related quality of life, symptoms, lung function, use of rescue medication and withdrawal rates. In some cases, the benefits reached accepted levels of clinical significance, but only just. Minimal clinical important differences (MCID) are sometimes used to help clinicians interpret trial findings in a meaningful way. The MCID for predose FEV<sub>1</sub> is thought to be approximately 100 mL (<a href="./references#CD003794-bbs2-0085" title="DonohueJF . Minimally clinically important differences in COPD lung function. COPD2005;2:111–24. ">Donohue 2005</a>). <a href="./references#CD003794-bbs2-0094" title="LeidyNK , RennardSI , SchmierJ , JonesMKC , GoldmanM . The Breathlessness, Cough, and Sputum Scale.* The Development of Empirically Based Guidelines for Interpretation. Chest2003;124:2182‐91. ">Leidy 2003</a> suggests that changes of 1.0 in the BCSS represent substantial symptomatic improvement, changes of approximately 0.6 can be interpreted as moderate and changes of 0.3 can be considered small. A four‐unit difference is the generally accepted MCID for SGRQ score (<a href="./references#CD003794-bbs2-0091" title="JonesPW . St. George's Respiratory Questionnaire: MCID. COPDMarch 2005;2(1):75‐9. ">Jones 2005</a>). Mean differences reflect an unknown range of results from individual participants, and although an MCID may be achieved on average, this neither confirms nor rules out meaningful improvement over placebo for all. Furthermore, for some of these outcomes, a high degree of heterogeneity was noted, some of which may be due to differences in study protocols. </p> </section> </section> <section id="CD003794-sec-0116"> <h3 class="title" id="CD003794-sec-0116">Overall completeness and applicability of evidence</h3> <p>Participants and outcomes reported were typical of those described for COPD patients. The most abundant evidence comes from studies on the FPS combination, which was the only one to show a mortality benefit. Fewer data are available for the MF/F combination, but nothing has been discovered to suggest that it behaves differently from the other inhalers. </p> <p>This review addresses the efficacy and safety of combined ICS and LABA in one inhaler versus placebo as a pair‐wise comparison. We did not seek to address the efficacy of the individual components (LABA and ICS) versus combined treatment, although such comparisons were included in some of studies in this review, notably the TORCH trial. In this large trial, it appears that the mortality benefit, while not reaching statistical significance, is driven largely by the LABA component of combined therapy. The efficacy of the individual components versus combined therapy is addressed in two linked Cochrane reviews (<a href="./references#CD003794-bbs2-0096" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>; <a href="./references#CD003794-bbs2-0097" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006826.pub2] ">Nannini 2013</a>) and will be included in a forthcoming network meta‐analysis (<a href="./references#CD003794-bbs2-0100" title="ObaY , FadilaM , KeeneyE , DiasS . Fixed‐dose combination inhalers compared to long‐acting bronchodilators for COPD: a network meta‐analysis (Protocol). Cochrane Database of Systematic Reviews2017, Issue 3. [DOI: 10.1002/14651858.CD012620] ">Oba 2017</a>). </p> </section> <section id="CD003794-sec-0117"> <h3 class="title" id="CD003794-sec-0117">Quality of the evidence</h3> <p>Most trials were industry‐sponsored. The risk of bias in blinding was considered low for all trials. The risk of bias from attrition was considered higher because of the number of participants withdrawn (over 20% in most trials), especially as this group may represent a more severely involved subgroup (<a href="./references#CD003794-bbs2-0093" title="KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30:898‐906. ">Kesten 2007</a>). In addition, we found significantly greater participant withdrawal in the placebo arm across all three combined inhalers (<a href="./references#CD003794-fig-0023" title="">Analysis 2.12</a>, <a href="./references#CD003794-fig-0054" title="">Analysis 3.16</a> and <a href="./references#CD003794-fig-0074" title="">Analysis 4.7</a>). However, the completion rate in the included trials was generally equal to, or better than, that of other trials involving participants with COPD. Selective reporting was generally considered to be of low risk. </p> <p>Intention‐to‐treat analyses were conducted in all studies, but for outcomes such as mean exacerbation rates, withdrawal of severe frequent exacerbators from the studies may have distorted study findings because of the lower exacerbation rates seen with active treatment. Loss of participants with more frequent exacerbations from the studies may thus limit the accuracy of mean event rates. The question of exacerbations and the appropriate statistical analysis of rate ratios cast some doubt regarding the validity of some of the findings in this review. In particular, the large long‐term studies (i.e. those in excess of six months), which are adequately powered to detect statistically significant findings, may overestimate the treatment effects of this therapy (<a href="./references#CD003794-bbs2-0102" title="SuissaS . Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2006;173(8):842‐6. ">Suissa 2006</a>). The method of weighting counts of exacerbations as described by <a href="./references#CD003794-bbs2-0102" title="SuissaS . Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2006;173(8):842‐6. ">Suissa 2006</a> (using duration of person follow‐up time as a denominator in calculating the mean group rate of exacerbations rather than an unweighted approach) was undertaken in <a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>;and <a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a>. In these studies, the effects were consistent and significantly favoured combination therapy over placebo. However, the major primary outcome after mortality rate was hospitalisation due to COPD exacerbation, and this did not show any difference between treatments. </p> <p>Visual inspection of a funnel plot for the mortality outcome does not suggest publication bias (<a href="#CD003794-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD003794-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.2 Mortality." data-id="CD003794-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.2 Mortality. </p> </div> </div> </div> </section> <section id="CD003794-sec-0118"> <h3 class="title" id="CD003794-sec-0118">Potential biases in the review process</h3> <p>The Cochrane Airways Group provided an excellent level of support in the identification of potentially relevant trials. To minimise the risk of selection and publication bias, an exhaustive search of the published literature and the unpublished literature, with no language restrictions, for potentially relevant clinical trials was underpinned by a systematic search strategy. Trial selection and data extraction followed a prespecified protocol, and the process was independently conducted by two review authors. Nevertheless, we acknowledge that additional unidentified trials may exist. </p> </section> <section id="CD003794-sec-0119"> <h3 class="title" id="CD003794-sec-0119">Agreements and disagreements with other studies or reviews</h3> <p>This Cochrane review confirms and builds upon an earlier one (<a href="./references#CD003794-bbs2-0109" title="NanniniL , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta‐agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD003794.pub2] ">Nannini 2004</a>) and upon related reviews (<a href="./references#CD003794-bbs2-0096" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>; <a href="./references#CD003794-bbs2-0097" title="NanniniLJ , PooleP , MilanSJ , KestertonA . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD006826.pub2] ">Nannini 2013</a>). For this update, we checked all previous data and added hospital admissions using COPD‐related serious adverse events as a surrogate marker. To enhance clarity, several outcomes in the FPS subgroup with few contributing studies have been deleted from the current update. We have added data for MF/F versus placebo, as these studies took place after the previous review. </p> <p>Our finding that combined inhaler therapy reduced death is concordant with that of another review of all inhaled medications in COPD, which concluded that ICS/LABA was associated with the lowest risk of death among all treatments (<a href="./references#CD003794-bbs2-0084" title="DongYH , LinHH , ShauWY , WuYC , ChangCH , LaiMS . Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta‐analysis of randomised controlled trials. ThoraxJan 2013;68(1):48‐56. ">Dong 2013</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003794-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD003794-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.1 Exacerbation rates with combined inhalers versus placebo." data-id="CD003794-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.1 Exacerbation rates with combined inhalers versus placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.2 Mortality." data-id="CD003794-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.2 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.3 Pneumonia." data-id="CD003794-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.3 Pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.4 Hospitalisations due to COPD exacerbations." data-id="CD003794-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.4 Hospitalisations due to COPD exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.2 Mortality." data-id="CD003794-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Combined inhalers versus placebo (primary outcomes), outcome: 1.2 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined inhalers versus placebo (primary outcomes), Outcome 1 Exacerbation rates with combined inhalers versus placebo." data-id="CD003794-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Combined inhalers versus placebo (primary outcomes), Outcome 1 Exacerbation rates with combined inhalers versus placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined inhalers versus placebo (primary outcomes), Outcome 2 Mortality." data-id="CD003794-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Combined inhalers versus placebo (primary outcomes), Outcome 2 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined inhalers versus placebo (primary outcomes), Outcome 3 Pneumonia." data-id="CD003794-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Combined inhalers versus placebo (primary outcomes), Outcome 3 Pneumonia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined inhalers versus placebo (primary outcomes), Outcome 4 Hospitalisations due to COPD exacerbations." data-id="CD003794-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Combined inhalers versus placebo (primary outcomes), Outcome 4 Hospitalisations due to COPD exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Combined inhalers versus placebo (primary outcomes), Outcome 5 Number of participants with at least one exacerbation." data-id="CD003794-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Combined inhalers versus placebo (primary outcomes), Outcome 5 Number of participants with at least one exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 1 Exacerbations." data-id="CD003794-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 1 Exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 2 Number of participants with at least one exacerbation." data-id="CD003794-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 2 Number of participants with at least one exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 3 Participants with at least one exacerbation by type." data-id="CD003794-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 3 Participants with at least one exacerbation by type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 4 Exacerbations by type." data-id="CD003794-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 4 Exacerbations by type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 5 Mortality." data-id="CD003794-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 5 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 6 Change from baseline in St George's Respiratory Questionnaire (total score)." data-id="CD003794-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 6 Change from baseline in St George's Respiratory Questionnaire (total score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 7 Change from baseline in Chronic Respiratory Disease Questionnaire scores." data-id="CD003794-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 7 Change from baseline in Chronic Respiratory Disease Questionnaire scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 8 Change from baseline in Transitional Dyspnoea Index (TDI) scores." data-id="CD003794-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 8 Change from baseline in Transitional Dyspnoea Index (TDI) scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 9 Change from baseline in predose FEV1." data-id="CD003794-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 9 Change from baseline in predose FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 10 Change from baseline in postdose FEV1." data-id="CD003794-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 10 Change from baseline in postdose FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 11 Change from baseline in rescue medication usage (puffs/d)." data-id="CD003794-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 11 Change from baseline in rescue medication usage (puffs/d). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 12 Withdrawals—total." data-id="CD003794-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 12 Withdrawals—total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 13 Withdrawals due to adverse events." data-id="CD003794-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 13 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 14 Withdrawals due to lack of efficacy." data-id="CD003794-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 14 Withdrawals due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 15 Adverse events—any." data-id="CD003794-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 15 Adverse events—any. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 16 Adverse events—'serious'." data-id="CD003794-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 16 Adverse events—'serious'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 17 Adverse events—pneumonia." data-id="CD003794-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 17 Adverse events—pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 18 Adverse events—candidiasis." data-id="CD003794-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 18 Adverse events—candidiasis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 19 Adverse events—hoarseness." data-id="CD003794-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 19 Adverse events—hoarseness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 20 Adverse events—palpitations." data-id="CD003794-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 20 Adverse events—palpitations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 21 Adverse events—blood glucose increased." data-id="CD003794-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 21 Adverse events—blood glucose increased. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 22 Adverse event—skin bruising." data-id="CD003794-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 22 Adverse event—skin bruising. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 23 Adverse events—bronchitis." data-id="CD003794-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 23 Adverse events—bronchitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 24 Adverse events—upper respiratory tract infection." data-id="CD003794-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 24 Adverse events—upper respiratory tract infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 25 Adverse events—nasopharyngitis." data-id="CD003794-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 25 Adverse events—nasopharyngitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 26 Adverse events—cough." data-id="CD003794-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 26 Adverse events—cough. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 27 Adverse events—headache." data-id="CD003794-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus placebo (PLA), Outcome 27 Adverse events—headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 1 Severe exacerbations." data-id="CD003794-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 1 Severe exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 2 Mean severe exacerbation rates per participant per year." data-id="CD003794-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 2 Mean severe exacerbation rates per participant per year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 3 Mortality." data-id="CD003794-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 3 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 4 Change from baseline in St George's Respiratory Questionnaire (total score)." data-id="CD003794-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 4 Change from baseline in St George's Respiratory Questionnaire (total score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 5 Quality of life—change scores." data-id="CD003794-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 5 Quality of life—change scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 6 Symptoms (change scores)." data-id="CD003794-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 6 Symptoms (change scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 7 Breathlessness, cough and sputum score (BCSS) change from baseline—average over treatment period." data-id="CD003794-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 7 Breathlessness, cough and sputum score (BCSS) change from baseline—average over treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 8 Rescue medication usage." data-id="CD003794-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 8 Rescue medication usage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 9 Mean FEV1 (% change from baseline)." data-id="CD003794-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 9 Mean FEV<sub>1</sub> (% change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 10 Average 12‐hour FEV1 change from baseline—end of treatment (L)." data-id="CD003794-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 10 Average 12‐hour FEV<sub>1</sub> change from baseline—end of treatment (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 11 Predose FEV1 [L] change from baseline to the average over the randomised treatment period." data-id="CD003794-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 11 Predose FEV<sub>1</sub> [L] change from baseline to the average over the randomised treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 12 1 Hour postdose FEV1 [L] change from baseline to the average over the randomised treatment period." data-id="CD003794-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 12 1 Hour postdose FEV<sub>1</sub> [L] change from baseline to the average over the randomised treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 13 FEV1 at 12‐hour change from baseline—end of treatment (L)." data-id="CD003794-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 13 FEV<sub>1</sub> at 12‐hour change from baseline—end of treatment (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 14 Morning PEFR change from baseline, average over treatment period (L/min)." data-id="CD003794-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 14 Morning PEFR change from baseline, average over treatment period (L/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 15 Evening PEFR mean change from baseline, average over treatment period (L/min)." data-id="CD003794-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 15 Evening PEFR mean change from baseline, average over treatment period (L/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 16 Withdrawals—total." data-id="CD003794-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 16 Withdrawals—total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 17 Withdrawals due to adverse events." data-id="CD003794-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 17 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 18 Withdrawals due to lack of efficacy." data-id="CD003794-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 18 Withdrawals due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 19 Adverse event—any." data-id="CD003794-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 19 Adverse event—any. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 20 Adverse events—'serious'." data-id="CD003794-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 20 Adverse events—'serious'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 21 Adverse events—pneumonia." data-id="CD003794-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 21 Adverse events—pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 22 Adverse events—candidiasis." data-id="CD003794-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 22 Adverse events—candidiasis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 23 Adverse events—dysphonia." data-id="CD003794-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 23 Adverse events—dysphonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 24 Adverse events—cataracts." data-id="CD003794-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 24 Adverse events—cataracts. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 25 Adverse events—COPD." data-id="CD003794-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 25 Adverse events—COPD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 26 Adverse events—tremor." data-id="CD003794-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 26 Adverse events—tremor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 27 Adverse events—palpitations." data-id="CD003794-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 27 Adverse events—palpitations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 28 Adverse events—lumbar spine bone density change from baseline (g/cm2)." data-id="CD003794-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.28</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 28 Adverse events—lumbar spine bone density change from baseline (g/cm<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-003-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-003-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 29 Adverse events—hip bone density change from baseline (g/cm2)." data-id="CD003794-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.29</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus placebo (PLA), Outcome 29 Adverse events—hip bone density change from baseline (g/cm<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-003-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 1 Number of participants with at least one exacerbation." data-id="CD003794-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 1 Number of participants with at least one exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 2 Number of participants having at least one moderate or severe exacerbation." data-id="CD003794-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 2 Number of participants having at least one moderate or severe exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 3 Mortality." data-id="CD003794-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 3 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 4 Change from baseline in St George's Respiratory Questionnaire (total score)." data-id="CD003794-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 4 Change from baseline in St George's Respiratory Questionnaire (total score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 5 Change from baseline in FEV1 AUC0–12 hours (mL)—week 13." data-id="CD003794-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 5 Change from baseline in FEV<sub>1</sub> AUC0–12 hours (mL)—week 13. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 6 Mean change from baseline AM predose FEV1 at 13 weeks (mL)." data-id="CD003794-fig-0073" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 6 Mean change from baseline AM predose FEV<sub>1</sub> at 13 weeks (mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 7 Withdrawals—total." data-id="CD003794-fig-0074" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 7 Withdrawals—total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 8 Withdrawals due to lack of efficacy." data-id="CD003794-fig-0075" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 8 Withdrawals due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 9 Withdrawals due to adverse events." data-id="CD003794-fig-0076" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 9 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 10 Adverse events—any." data-id="CD003794-fig-0077" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 10 Adverse events—any.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 11 Adverse events—serious." data-id="CD003794-fig-0078" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 11 Adverse events—serious.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 12 Adverse events—pneumonia." data-id="CD003794-fig-0079" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 12 Adverse events—pneumonia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 13 Adverse events—candidiasis." data-id="CD003794-fig-0080" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 13 Adverse events—candidiasis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 14 Adverse events—dysphonia." data-id="CD003794-fig-0081" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 14 Adverse events—dysphonia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 15 Adverse events—cataract." data-id="CD003794-fig-0082" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 15 Adverse events—cataract.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003794-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/urn:x-wiley:14651858:media:CD003794:CD003794-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_t/tCD003794-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 16 Adverse events—COPD requiring hospitalisation." data-id="CD003794-fig-0083" src="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus placebo, Outcome 16 Adverse events—COPD requiring hospitalisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/media/CDSR/CD003794/image_n/nCD003794-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003794-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Combined inhalers versus placebo (primary outcomes) for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combined inhalers versus placebo (primary outcomes) for chronic obstructive pulmonary disease (COPD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with COPD<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> combined inhalers </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Combined inhalers versus placebo (primary outcomes)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Annual exacerbation rates</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1.35</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0.99</b> </p> <p>(0.93 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate ratio 0.73</b> </p> <p>(0.69 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7473</p> <p>(seven studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1, 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants with at least one exacerbation</b> </p> <p><b>Duration of six months<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>301 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>251 per 1000</b> </p> <p>(221 to 286)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.78</b> <br/> (0.66 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3141</p> <p>(eight studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> <p><b>Duration of 18 months<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b><br/> (41 to 59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.82</b> <br/> (0.68 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10129<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia</b> </p> <p><b>Duration of 18 months<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>85 per 1000</b><br/> (73 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.62</b> <br/> (1.36 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9620<br/> (14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisations due to COPD exacerbations</b> </p> <p><b>Duration of 18 months<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>115 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>108 per 1000</b><br/> (95 to 121) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.93</b> <br/> (0.81 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9492<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3, 5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded because of risk of attrition bias. </p> <p><sup>2</sup>Concerns have been raised about the analysis of the largest study, TORCH. We note that the protocol was published after the trial had recruited (See <a href="#CD003794-sec-0135">Feedback 1</a>, <a href="#CD003794-sec-0139">Feedback 2</a>). No downgrade. </p> <p><sup>3</sup>Weighted mean duration. </p> <p><sup>4</sup>Downgraded because of imprecision. </p> <p><sup>5</sup>Downgraded because of risk of attrition bias and imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Combined inhalers versus placebo (primary outcomes) for chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003794-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fluticasone/salmeterol (FPS) versus placebo for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fluticasone/salmeterol (FPS) versus placebo for COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with COPD<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> fluticasone/salmeterol (FPS) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fluticasone/salmeterol (FPS) versus placebo (PLA)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>any</b> </p> <p><b>Duration of two years<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>780 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>794 per 1000</b><br/> (771 to 816) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.09</b> <br/> (0.95 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5574<br/> (nine studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>'serious'</b> </p> <p><b>Duration of two years<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>271 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>287 per 1000</b><br/> (261 to 314) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.08</b> <br/> (0.95 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5531<br/> (nine studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Weighted mean duration. </p> <p><sup>2</sup>Downgraded because of risk of attrition bias and imprecision. </p> <p><sup>3</sup>Concerns have been raised about the analysis of the largest study, TORCH. We note that the protocol was published after the trial had recruited (See <a href="#CD003794-sec-0135">Feedback 1</a>, <a href="#CD003794-sec-0139">Feedback 2</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fluticasone/salmeterol (FPS) versus placebo for COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003794-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Budesonide/formoterol (BDF) versus placebo for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Budesonide/formoterol (BDF) versus placebo for COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with COPD<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> budesonide/formoterol (BDF) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Budesonide/formoterol (BDF) versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> —<b>any</b> —<b>320/9<sup>4</sup> </b> </p> <p><b>Duration of nine months <sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>538 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b><br/> (574 to 669) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.42</b> <br/> (1.16 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1552<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> —<b>any</b> —<b>160/9<sup>4</sup> </b> </p> <p><b>Duration of nine months <sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>538 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>606 per 1000</b><br/> (557 to 652) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.32</b> <br/> (1.08 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>'serious'</b> —<b>320/9<sup>4</sup> </b> </p> <p><b>Duration of 10 months<sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>162 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b><br/> (155 to 219) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.17</b> <br/> (0.95 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2476<br/> (four studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>'serious'</b> —<b>160/9<sup>4</sup> </b> </p> <p><b>Duration of nine months <sup>3</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b><br/> (102 to 171) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.2</b> <br/> (0.89 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1556<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded because of risk of attrition bias and imprecision and heterogeneity.<br/> <sup>2</sup>Downgraded because of risk of attrition bias and imprecision. </p> <p><sup>3</sup>Weighted mean duration. </p> <p><sup>4</sup>Delivered dose. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Budesonide/formoterol (BDF) versus placebo for COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003794-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Mometasone/formoterol (MF/F) versus placebo for COPD</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Mometasone/formoterol (MF/F) versus placebo for COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic obstructive pulmonary disease<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> mometasone/formoterol (MF/F) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Mometasone/formoterol (MF/F) versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> —<b>any</b> —<b>400/10<sup>3</sup> </b> </p> <p><b>Duration of six months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>362 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>357 per 1000</b><br/> (298 to 424) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.98</b> <br/> (0.75 to 1.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>890<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> —<b>any</b> —<b>200/10<sup>3</sup> </b> </p> <p><b>Duration of six months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>362 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>317 per 1000</b><br/> (260 to 382) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.82</b> <br/> (0.62 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>894<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>serious</b> —<b>400/10<sup>3</sup> </b> </p> <p><b>Duration of six months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b><br/> (50 to 125) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.09</b> <br/> (0.66 to 1.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>890<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> —<b>serious</b> —<b>200/10<sup>3</sup> </b> </p> <p><b>Duration of six months</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b><br/> (32 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.71</b> <br/> (0.41 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>894<br/> (two studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded because of risk of attrition bias, imprecision and heterogeneity.<br/> <sup>2</sup>Downgraded because of risk of attrition bias and imprecision. </p> <p><sup>3</sup>Delivered dose. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Mometasone/formoterol (MF/F) versus placebo for COPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003794-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Version</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Detail</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First published version—Issue 4, 2003 (all years to April 2002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 34<br/> References retrieved: seven<br/> Studies excluded: three (Cazzola 2000; Chapman 2002; Soriano 2002)<br/> Studies identified from supplementary searching: four (Dal Negro 2003; Hanania 2003—both included; Cazzola 2002a; Cazzola 2004—both excluded).<br/> Studies included: four </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Second published version—Issue 3, 2004 (April 2003 to April 2004)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 12<br/> References retrieved: three (two papers full publications of previously included or cited studies (Dal Negro 2003; Hanania 2003). Handsearching identified two further references to the COSMIC 2003 study<br/> Studies identified from supplementary searching: one (TRISTAN 2003)<br/> New studies included: two<br/> Total studies included: six </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Third published version—Issue 3, 2005 (April 2004 to April 2005)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 52<br/> References retrieved: 46 (references to studies already included/excluded/ongoing: 24)<br/> New unique studies identified: 10 (ongoing studies: two)<br/> New studies included: zero<br/> Total studies included: six </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fourth published version (April 2005 to April 2007)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 66<br/> References retrieved: 27 (references to studies already included/excluded/ongoing)<br/> New unique studies identified: five (ongoing studies: zero)<br/> New studies included: five<br/> Total studies included: 11 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fifth published version (April 2007 to June 2013)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 129</p> <p>New unique studies identified: eight (ongoing studies: zero)</p> <p>New studies included: eight</p> <p>Total studies included: 19</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003794-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rates and NNTB of mortality and NNTH of pneumonia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo rate (%)</b> </p> <p><b>mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNTB for mortality</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo rate (%)</b> </p> <p><b>pneumonia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNTH for pneumonia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0017" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The Towards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years. Respirology2006;11(Suppl 5):A149. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (towards a revolution in COPD health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28(Suppl 50):34s. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11(Suppl 5):A140. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The towards a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 6:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2007):A839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study. http://www.abstracts2view.com (accessed 1 April 2004):A122. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The towards study a revolution in COPD health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . Survival of subjects with chronic obstructive pulmonary disease (COPD). http://clinicaltrials.gov/show/NCT00268216 (accessed 9 July 2013). [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. http://www.gsk‐clinicalstudyregister.com/quick‐search‐list.jsp?tab=results&amp;letterrange=All&amp;type=GSK+Study+ID&amp;item=SCO30003&amp;studyType=All&amp;phase=All&amp;status=All&amp;population=All&amp;marketing=All&amp;country=All&amp;studyId=SCO30003 (accessed 9 July 2013). VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. VestboJ , The TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial. http://www.abstracts2view.com (accessed 1 April 2007):A120. ">TORCH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42 (24 to 775)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (27 to 12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0018" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A98 [Poster 306]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD.. American Thoracic Society 99th International Conference; May 16‐21; Seattle2003:A035 [Poster D50]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference; May 17‐22; Atlanta. 2002:A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. 13th ERS Annual Congress, 27 Spetember, Vienna. 2003:P1593. MorganM . Salmetrol xinafoate/fluticasone propionate combination product in the treatment of chronic obstructive pulmonary disease. Publication ID: N0123137844 http://www.nihr.ac.uk/Profile/Pages/NRRResults.aspx?publication_id=N0123137844 (accessed 9 July 2013). NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol/fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com(accessed 2003). PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register http:ctr.gsk.co.uk(accessed 2005). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 Hours in moderate to severe COPD. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>292 (164 to 5256)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197 (339 to 131)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0003" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/drug‐products/drugproducts/?itemId=8574657 (accessed 8 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPM , SzafranskiW , Andersson , CalverleyPMA , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD [Abstract]. European Respiratory Journal2005; Vol. 26 Suppl 49:Abstract No. 1917. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐12; Seattle. 2003:B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:D092 [Poster 211]. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005:B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21; Seattle. 2003:B024 [Poster 419]. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; 27 September; Vienna. 2003:P1586. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>249 (149 to 1307)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48 (82 to 32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0014" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). http://www.astrazenecaclinicaltrials.com/diseases‐and‐conditions/diseaseandconditions/?itemId=8574657 (accessed 9 June 2013). BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. BTS Winter Meeting; London. December 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. BTS Winter Meeting. London. 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. BTS Winter Meeting. London. 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>110 (66 to 581)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0010" title="A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 × 160/4.5 mcg bid and 2 × 80/4.5mcg bid compared to formoterol TBH 2 × 4.5 mcg bid and placebo in patients with COPD. http://www.astrazenecaclinicaltrials.com/therapy‐areas/respiratory‐inflammation/?itemId=8574296 (accessed 8 June 2013). LatiesA , RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (bud/fm pmdi) on ophthalmologic assessments in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:468A. NCT00206167 . A 12‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2 × 160/4.5 Î¼g Bid and 2 × 80/4.5 Î¼g Bid compared to Formoterol Turbuhaler® 2 × 4.5 Î¼g Bid and placebo in patients with COPD. http://clinicaltrials.gov/show/NCT00206167 (accessed 8 June 2013). [] RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1‐year randomized controlled clinical trial. Drugs. Adis Data Information BV., 2009; Vol. 69, issue 5:549‐65. RennardSI , TashkinDP , McElhattanJ , GoldmanM , SilkoffPE . Long‐term tolerability of budesonide and formoterol administered in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4_MeetingAbstracts:p103001. RennardSI , TashkinDP , SuchowerLJ , MartinUJ . Effect of budesonide/formoterol pressurized metered‐dose inhaler (BUD/FM pMDI) on bone mineral density (BMD) in moderate to very severe chronic obstructive pulmonary disease (COPD) patients: results from a 1‐year, randomized, controlled clinical trial [Abstract]. Chest2010; Vol. 138, issue 4:863A. ">Rennard 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>674 (379 to 12,149)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (63 to 25)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0015" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 14:1975‐2000. ">Tashkin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1689 (950 to 30,403)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>164 (282 to 109)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0005" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7:57‐71. NCT00383721 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383721 (accessed 10 June 2013). [] ">Doherty 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>659 (370 to 11,865)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>193 (331 to 128)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0016" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A randomized, 26‐week, placebo‐controlled efficacy and safety study with a 26‐week long‐term safety extension, of high‐ and medium‐dose inhaled mometasone furoate/formoterol fixed‐dose combination formulation compared with formoterol and high‐dose inhaled mometasone furoate monotherapy in subjects with moderate to severe COPD. http://clinicaltrials.gov/show/NCT00383435 (accessed 9 June 2013). [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012;7:43‐55. ">Tashkin 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1187 (668 to 21,377)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>346 (595 to 229)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0008" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 1 April 2004). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate (FP) 500mcg BID individually and in combination as Salmeterol 50mcg/Fluticasone Propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SFCA3006&amp;studyId=ECBB8395‐5CCB‐410C‐91DA‐1420726FB071&amp;compound=fluticasone+propionate%2Fsalmeterol&amp;type=Compound&amp;letterrange=A‐F (accessed 8 June 2013). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25; San Diego. 2005. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>340 (191 to 6125)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003794-bbs2-0009" title="CelliB , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28(Suppl 50):764s. MakeB , EmmettA , CraterG , O'DellD , KalbergC . Improvement in exercise endurance time (EET) with fluticasone propionate/salmeterol correlations with spirometry and plethysmography. Proceedings of the American Thoracic Society; May 19‐24; San Diego. 2006. O'DonnellDE , SciurbaF , CelliB , MahlerDA , WebbKA , KalbergCJ , et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest2006;130(3):647‐56. SCO40030 . A randomized, double‐blind, placebo‐controlled, parallel group clinical trial evaluating the effect of the fluticasone propionate/salmeterol combination product 250/50mcg bid via DISKUS and salmeterol 50mcg bid via DISKUS on lung hyperinflation in subjects with chronic obstructive pulmonary disease (COPD). http://www.gsk‐clinicalstudyregister.com/result_detail.jsp?protocolId=SCO40030&amp;studyId=8CE29C37‐5F7D‐4461‐B1A6‐1A1FDA5981A6&amp;compound=SCO40030&amp;type=GSK+Study+ID&amp;letterrange=All (accessed 10 June 2013). ">O'Donnell 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107 (182 to 71)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rates and NNTB of mortality and NNTH of pneumonia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/full#CD003794-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003794-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Combined inhalers versus placebo (primary outcomes)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbation rates with combined inhalers versus placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.69, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fluticasone/salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.69, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Budesonide/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.62, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.68, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fluticasone/salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.65, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Budesonide/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.57, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Mometasone/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.36, 5.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.36, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fluticasone/salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.46, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Budesonide/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.57, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Mometasone/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.68, 8.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Hospitalisations due to COPD exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.80, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Fluticasone/salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.75, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Budesonide/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.87, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Mometasone/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.31, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants with at least one exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.66, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Fluticasone/salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.64, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mometasone/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.58, 0.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Combined inhalers versus placebo (primary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003794-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fluticasone/salmeterol (FPS) versus placebo (PLA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.69, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.69, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants with at least one exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.64, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.06, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.69, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.54, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.09, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants with at least one exacerbation by type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Requirement for oral steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.61, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Requirement for antibiotic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.26, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Requirement for oral steroid or antibiotic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.32 [0.13, 82.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.32 [0.13, 82.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Exacerbations by type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Requirement for oral steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.52, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Requirement for antibiotic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.41, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.70, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.65, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Mortality: three‐year data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.66, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Mortality: one‐year data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.13, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Mortality: six‐month data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.11, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Mortality: three‐month data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change from baseline in St George's Respiratory Questionnaire (total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐3.61, ‐2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐3.61, ‐2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change from baseline in Chronic Respiratory Disease Questionnaire scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [2.48, 7.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [2.48, 7.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change from baseline in Transitional Dyspnoea Index (TDI) scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.56, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>707</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.56, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change from baseline in predose FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.14, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.15, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.11, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Change from baseline in postdose FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.07, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.07, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Change from baseline in rescue medication usage (puffs/d) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.19 [‐1.83, ‐0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.19 [‐1.83, ‐0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Withdrawals—total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.62, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [0.30, 29.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.60, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.60, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.25, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.64, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.01, 8.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.31, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.65, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.11, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.22, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.08, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.21, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.08, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse events—any <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.95, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.59, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.03, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.88, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.19, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse events—'serious' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.95, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.05, 6.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Partially reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.38, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.97, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse events—pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.49, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.55 [0.26, 116.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.48, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.31 [0.13, 83.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse events—candidiasis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.73 [3.07, 10.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.06, 16.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.13 [3.36, 36.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.40 [2.01, 9.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse events—hoarseness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.61, 4.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>585</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.61, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse events—palpitations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse events—blood glucose increased <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse event—skin bruising <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse events—bronchitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse events—upper respiratory tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4963</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.04, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.81, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.02, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse events—nasopharyngitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.05, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.05, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse events—cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.23, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.15 [0.13, 78.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>346</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.18, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.04, 3.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse events—headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.84, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.02, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.91, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.73, 1.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fluticasone/salmeterol (FPS) versus placebo (PLA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003794-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Budesonide/formoterol (BDF) versus placebo (PLA)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Severe exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.62, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Poorly reversible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.62, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean severe exacerbation rates per participant per year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.57, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change from baseline in St George's Respiratory Questionnaire (total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.73 [‐4.83, ‐2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.39 [‐4.70, ‐2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life—change scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>SGRQ (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.06 [‐7.90, ‐4.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Poorly reversible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>SGRQ (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.06 [‐7.90, ‐4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Symptoms (change scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Symptom scale (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐0.90, ‐0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Poorly reversible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Symptom scale (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐0.90, ‐0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Breathlessness, cough and sputum score (BCSS) change from baseline—average over treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1533</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.59, ‐0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐0.60, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Rescue medication usage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.98 [‐1.18, ‐0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.28 [‐1.55, ‐1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mean FEV<sub>1</sub> (% change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.40 [11.91, 16.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Poorly reversible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.40 [11.91, 16.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Average 12‐hour FEV<sub>1</sub> change from baseline—end of treatment (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.12, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.10, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Predose FEV<sub>1</sub> [L] change from baseline to the average over the randomised treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.04, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.03, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 1 Hour postdose FEV<sub>1</sub> [L] change from baseline to the average over the randomised treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.14, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.13, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 FEV<sub>1</sub> at 12‐hour change from baseline—end of treatment (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.1 [0.03, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.00, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Morning PEFR change from baseline, average over treatment period (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.12 [15.69, 22.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.63 [11.47, 17.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Evening PEFR mean change from baseline, average over treatment period (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.09 [12.61, 19.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.74 [9.56, 15.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Withdrawals—total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.48, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.50, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.61, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.34, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.60, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse event—any <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.16, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.08, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse events—'serious' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.95, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.89, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse events—pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.52, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.45, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse events—candidiasis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.45 [1.88, 6.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.07, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse events—dysphonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.07 [1.52, 10.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.37, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse events—cataracts <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [0.18, 21.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse events—COPD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.69, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.88, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Adverse events—tremor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.55 [0.39, 146.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Adverse events—palpitations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.26 [0.13, 80.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Adverse events—lumbar spine bone density change from baseline (g/cm<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.03, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Adverse events—hip bone density change from baseline (g/cm<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 320/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 160/9 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Budesonide/formoterol (BDF) versus placebo (PLA)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003794-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mometasone/formoterol (MF/F) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants with at least one exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.54, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>886</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.58, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants having at least one moderate or severe exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.38, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>886</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.42, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.41, 7.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.20, 4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change from baseline in St George's Respiratory Questionnaire (total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐5.75, ‐1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.91 [‐6.01, ‐1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change from baseline in FEV<sub>1</sub> AUC0–12 hours (mL)—week 13 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>162.04 [126.54, 197.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>122.01 [86.64, 157.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean change from baseline AM predose FEV<sub>1</sub> at 13 weeks (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>114.64 [77.79, 151.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>70.43 [33.63, 107.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals—total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.40, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.40, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.08, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.11, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.58, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.16, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse events—any <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.75, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.62, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse events—serious <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.66, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.41, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events—pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.14 [0.84, 11.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.40, 7.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse events—candidiasis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.22 [0.50, 9.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.17, 5.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse events—dysphonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.19, 23.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.18, 22.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse events—cataract <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse events—COPD requiring hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 400/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.40, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 200/10 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.15, 0.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mometasone/formoterol (MF/F) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003794.pub4/references#CD003794-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003794.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003794-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003794-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003794-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003794\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003794\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003794\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003794\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003794\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1pyM3CVc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003794.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003794.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003794.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003794.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003794.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713866766"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003794.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713866770"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003794.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d60b4184b936e',t:'MTc0MDcxMzg2Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 